The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2021

The Functional Contribution Of Adaptive Immunity In The Biology
Of Pancreatic Cancer And Therapeutic Targeting Of Oncogenic
Kras
Krishnan Mahadevan

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medicine and Health Sciences Commons

Recommended Citation
Mahadevan, Krishnan, "The Functional Contribution Of Adaptive Immunity In The Biology Of Pancreatic
Cancer And Therapeutic Targeting Of Oncogenic Kras" (2021). The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open
Access). 1101.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1101

This Dissertation (PhD) is brought to you for free and
open access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

The Functional Contribution Of Adaptive Immunity In The Biology Of Pancreatic
Cancer And Therapeutic Targeting
Of Oncogenic Kras
By
Krishnan K. Mahadevan, M.B.B.S*
APPROVED:

______________________________
Raghu Kalluri, M.D., Ph.D.
Advisory Professor
______________________________
Huamin Wang, M.D., Ph.D.
______________________________
Florencia McAllister, M.D.
______________________________
Jennifer Wargo, M.D.
______________________________
Robert R. Jenq, M.D.

--------------------------------------------------------------------------------------------APPROVED:

____________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences

THE FUNCTIONAL CONTRIBUTION OF ADAPTIVE IMMUNITY IN THE BIOLOGY
OF PANCREATIC CANCER AND THERAPEUTIC TARGETING
OF ONCOGENIC KRAS

A
DISSERTATION
Presented to Faculty of
The University of Texas
MD Anderson Cancer Center UT Health
Graduate School of Biomedical Sciences
in Partial Fulfillment
of the Requirements
for the Degree of
DOCTOR OF PHILOSOPHY

By

Krishnan K. Mahadevan, M.B.B.S
Houston, Texas
May 2021

Dedication

This thesis work is dedicated to the memory of my late grandfather, Kalyana
Sundaram, who always inspires me and believed in my ability to be successful in the
academic arena.

iii

Acknowledgements
I feel deeply thankful for the guidance and support of several people throughout my
graduate study. First, I am very grateful and lucky to be mentored by Dr. Raghu Kalluri.
Dr. Kalluri has been a tremendous source of inspiration to me as a scientist, innovator
and entrepreneur. When I joined the Kalluri lab family in March 2016, he put me under
rigorous training with the most productive members of his scientific team. The amount
of resources that he spent on my projects were staggeringly colossal, without which
such elaborate disease models would have been impossible to generate and maintain.
The patience and support that I received from him during failed experiments and
negative results is something that I will never forget. Despite his busy schedule, I am
also extremely appreciative of the time Dr. Kalluri invested in me for review of
experiments, data analysis and mentoring me to scientifically think to develop
experiments that would take the project to new heights. These years under his
mentorship have not only made me a better scientist, but also instilled in me teamspirit, the importance of dedicated effort and collaboration.
Next, I would like to thank Dr. Hikaru Sugimoto for his invaluable help with animal
experiments, histological analysis and data interpretation. I am extremely grateful to Dr.
Valerie LeBleu for her encouragement and mentoring me with data review, manuscript
writing and intellectual inputs for my project. The scientific rigor and dedication to
precision are qualities in her that I would like to emulate as a scientist.

iv

My advisory committee, consisting of Dr. Huamin Wang, Dr. Andrew Rhim, Dr. Jennifer
Wargo, Dr. Florencia McAllister and Dr. Robert Jenq has constantly been a source of
support, information and inspiration. Their ability to propose innovative ideas, and vett
my research during committee meetings is a major reason for the progression of my
project. Despite incredibly busy schedules, they always set aside time to talk with me
and guide me, something that I consider extremely valuable. The variety of fields they
specialize in, has helped me develop into the all-round scientist. I am also extremely
appreciative of Dr. Robert Jenq and his lab members, Dr. Chia-Chi Chang and Dr.
Mohammad Jamal in particular for collaboration with microbiome project.
I would like to thank Dr. Elena Ramirez in particular, from the LeBleu lab and Kalluri lab
for her collaboration and help with flow cytometry and data analysis. I’m also extremely
appreciative of all the people that have helped me with my PhD project, in particular
Sujuan Yang, Dr. Xiaofeng Zheng, Dr. Yang Chen, Dr. Julienne Carstens, Lisa Becker,
Dr. Sushrut Kamekar, Lisa Norberg, Michelle Kirtley, Dr. Mayela Mendt, Dr. Olga
Volpert and Patricia Philip. I would also like to thank Dr. Adrienne Duran, Martha
Taghavi and Vivien Tran for help with in vivo imaging and animal care.
My friends, Alex Li, Deevakar and Rumi Lee have always been a source of immense
support throughout these years of my graduate study. Finally, I thank my loving wife
and parents for their caring support, encouragement and motivation. Without them, it
would not have been possible to overcome the challenges of the graduate school
experience.

v

Table of contents
Approvals page_______________________________________________________i
Title page___________________________________________________________ii
Dedication __________________________________________________________iii
Acknowledgements __________________________________________________iv
Table of contents_____________________________________________________vi
Abstract ____________________________________________________________1
Chapter 1: Background and significance_________________________________4
Pancreatic cancer disease burden and mortality _______________________5
Pancreatic cancer - risk factors and disease staging ___________________7
Genetic alterations in pancreatic cancer _____________________________9
Acinar to ductal metaplasia and pancreatic intraepithelial neoplasia _______12
Current therapies in pancreatic cancer______________________________12
T cells and myeloid cells in the pancreatic tumor microenvironment _______14
Kras* in the pancreatic tumor microenvironment ______________________18
Kras* targeting using iExosomes __________________________________18
Factors affecting T cell function in the pancreatic tumor
Microenvironment i) Microbiome___________________________________19
ii) Pancreatitis ________________________________________________21
Chapter 2: Material and methods ______________________________________23
Animal studies i) PiKP and PiKT mice ______________________________24

vi

ii) KPC CD4-/- and KPC CD8-/- mice ________________________________24
iii) Microbiome experiments ______________________________________25
Tissue processing _____________________________________________26
Immunotyping ________________________________________________26
Immunofluorescence ___________________________________________30
Immunohistochemistry__________________________________________32
Cell lines_____________________________________________________34
Pancreatic enzyme assays_______________________________________34
16S rRNA gene sequencing and bioinformatics analysis________________34
Statistics ____________________________________________________35
Results___________________________________________________________36
Chapter 3: Kras* drives a T cell deficient and myeloproliferative
PDAC TME _______________________________________________________37
i)

Kras* is required for progression and maintenance

of PDAC tumors ______________________________________________37
ii)

Kras* represses T cells and promotes myeloid infiltration

in PiKP mice _________________________________________________41
iii)

Kras* represses T cells and promotes myeloid infiltration

in PiKT mice _________________________________________________43
Chapter 4: CD4+ T cells impede the therapeutic efficacy of Kras*
targeting in PDAC _________________________________________________45
i)

CD4+ and CD8+ T cells do not alter primary tumor growth

or survival, but CD4+T cells promote metastasis in PDAC ______________45
ii)

iExosomes targeting Kras* increase T cell infiltration in PDAC _____48

iii)

CD4+ T cells impede the therapeutic efficacy of
vii

iExosomes in PDAC ___________________________________________49
Chapter 5: The gut microbiome co-operates with CD4+ T cells to
impede Kras* targeting in PDAC _____________________________________53
Chapter 6: CD4+ T cells promote tumorigenesis in KC mice with
pancreatitis but has not impact on spontaneously developing tumors______57
i)

CD4+ T cells promote tumorigenesis in

KC mice with acute pancreatitis__________________________________57
ii)

CD4+ T cells promote tumorigenesis in

KC mice with chronic pancreatitis_________________________________60
iii)

Kras* protects the pancreas against acute pancreatic injury_______61

Chapter 7: CD4+ T cells regulate dendritic cells to facilitate
pancreatic tumorigenesis in mice with pancreatitis______________________64
1.

i)

Pancreatitis recruits CD11c+ dendritic cells to the PDAC TME _____64

2.

ii)

CD4+ T cells regulate dendritic cells to drive tumor

initiation in mice with acute pancreatitis ____________________________66
3.

iii)

Pancreatitis renders the pancreatic TME sensitive to

Checkpoint blockade___________________________________________67
Summary of results ________________________________________________69
Chapter 8: Discussion ______________________________________________71
Role of Kras* in shaping the PDAC TME ___________________________71
Role of CD4+ T cells in PDAC progression__________________________72
Adaptive immune response and gut microbiome
in Kras* targeting therapy _______________________________________74
Impact of pancreatitis on adaptive immune response in PDAC __________75
Role of dendritic cells in sensitizing the PDAC TME to immunotherapy____77
viii

Conclusion __________________________________________________77
Bibliography _________________________________________________78
VITA________________________________________________________91

List of Illustrations
Fig. 1: Pancreatic cancer – Disease burden and mortality______________________6
Fig. 2: Pancreatic cancer – risk factors and disease staging____________________8
Fig. 3: Principle genetic alterations in pancreatic ductal adenocarcinoma _________11
Fig. 4: Current therapies in pancreatic cancer ______________________________14
Fig. 5: T cells and myeloid cells in the pancreatic tumor microenvironment________17

Table 1a: Antibodies used for flow cytometry _______________________________27
Table 1b: Phenotyping of cells in flow cytometry analysis______________________29
Table 2a: T cell panel TSA staining ______________________________________31
Table 2b: Phenotyping of cells in TSA analysis______________________________31
Table 3: Immunohistochemistry__________________________________________33

R Fig. 1: Kras* is required for progression and maintenance of PDAC tumors

____38

R Fig. 2: Histopathology of PiKT and PiKP GEMMs __________________________40
R Fig. 3: Kras* represses T cells and promotes myeloid infiltration in PiKP tumors __42
R Fig. 4: Kras* represses T cells and promotes myeloid infiltration in PiKT tumors __44
R Fig. 5: KPC CD4-/- and KPC CD8-/- mice lack respective T cell populations in
ix

the tumor and lymphoid organs _________________________________________46
R Fig. 6: CD4+ and CD8+ T cells do not alter primary tumor growth or survival,
but CD4+ T cells promote metastasis in PDAC _____________________________47
R Fig. 7: iExosomes targeting Kras* increases T cell infiltration in PDAC _________49
R Fig. 8: CD4+ T cells impede the therapeutic effects of iExosomes in PDAC _____51
R Fig. 9. Kaplan-Meier survival curves of KPC, KPC CD4-/- and KPC CD8-/mice treated with iExosomes __________________________________________52
R Fig. 10: The gut microbiome co-operates with CD4+ T cells to
impede Kras* targeting in PDAC ________________________________________55
R Fig. 11: Baseline radiance and microbiome composition of B6 and
CD4-/- mice treated with antibiotics ______________________________________56
R Fig. 12: CD4+ T cells promote tumorigenesis in KC mice with
acute pancreatitis ____________________________________________________59
R Fig. 13: CD4+ T cells promote tumorigenesis in KC mice with
chronic pancreatitis __________________________________________________61
R Fig. 14: Kras* protects the pancreas against acute pancreatic injury ___________63
R Fig. 15: Pancreatitis recruits activated dendritic cells to the
tumor microenvironment ______________________________________________65
R Fig. 16: CD4+ T cells regulate dendritic cells to drive tumor
initiation in mice with underlying pancreatitis ______________________________67
R Fig. 17: Pancreatitis renders the pancreatic TME sensitive
to checkpoint blockade. ______________________________________________68

x

The Functional Contribution Of Adaptive Immunity In The Biology Of Pancreatic Cancer
And Therapeutic Targeting
Of Oncogenic Kras
Krishnan K. Mahadevan M.B.B.S*
Advisory professor: Dr. Raghu Kalluri
Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer
related

deaths

in

the

USA(https://seer.cancer.gov/statfacts/html/pancreas.html),

whereby survival remains poor despite advances in surgical technique and new
combination chemotherapies. Immune checkpoint blockade has revolutionized the
treatment of cancers such as melanoma, bladder cancer and non-small cell lung
carcinomas. Unfortunately, PDAC is among the tumor types that remain refractory to
checkpoint immunotherapy(Royal et al., 2010, Le et al., 2013), with no survival benefits
in clinical trials and pre-clinical animal models of PDAC(Winograd et al., 2015). Failure
to respond to checkpoint blockade is frequently attributed to an immunosuppressive
tumor microenvironment (TME), low neo-epitope burden and lack of tumor infiltrating T
cells resulting from a desmoplastic stroma(McAllister et al., 2014, Zhang et al., 2014).
However, the molecular underpinnings of immunosuppression in PDAC remain poorly
understood.
Oncogenic Kras (Kras*, KrasG12D and other mutations), a key driver of PDAC is
thought to play an important role in creating an immunosuppressive TME(Zhang et al.,
2014, McAllister et al., 2014); however, its precise function in shaping the immune
landscape of PDAC remains elusive. There is no clear understanding of the functional
contribution of T cells and the nodes of regulation of immune infiltration in PDAC. In order
to exploit the full potential of the immune system to treat PDAC, it is urgent to generate
in vivo models that enables us functionally probe the role of oncogenic Kras in shaping
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the TME with an inducible and pancreas specific model expressing Kras*. We
demonstrate that Kras* contributed to a T cell deficient and myeloprofilerative TME in
PDAC. Next, we generate models that closely mimic human PDAC and allow depletion
of specific T cell subsets (CD4 and CD8+ T cells). Such models offer a unique modality
to interrogate the role of specific T cell subsets in PDAC progression and inform the
development of effective immunotherapy approaches for PDAC. We employ a Kras*
targeting agent (iExosomes) in the T cell depletion models to demonstrate that
combination of Kras* and CD4+ T cell targeting strategies resulted in robust tumor growth
inhibitory response. Further, we show how the gut microbiome modulates T cell
responses in the context of Kras* targeting in PDAC.
In the second part of our study, we determine how the presence of pancreatitis
alters the TME and the course of progression of PDAC. A significant portion of PDAC
patients have been reported to present with underlying chronic pancreatitis and bile
duct obstruction. However, current therapeutic strategies do not consider the influence
of chronic pancreatitis while stratifying PDAC patients in clinical trials. The presence of
chronic inflammation in a cancer setting could recruit a unique immune signature to the
TME and open new possibilities for immune modulation in these PDAC patients.
Therefore, we investigate how pancreatitis impacts tumor progression and modulates
the immune landscape of the PDAC microenvironment. We demonstrate that
pancreatitis accelerates tumorigenesis in mice with Kras* mutant pancreas and recruits
activated dendritic cells to the tumor microenvironment. However, CD4+ T cells
promote pancreatic tumorigenesis in mice with pancreatitis by regulating dendritic cells
in the TME. Further, we demonstrate that presence of pancreatitis sensitizes the
pancreatic immune microenvironment to checkpoint blockade.

2

Overall, our study offers novel mechanistic insights into how Kras* modulates
the immune microenvironment and unravels potential therapeutic windows to synergize
Kras* and CD4+ T cell targeting approaches. Further, our study offers insights into how
presence of pancreatitis alters immune microenvironment, suggesting stratification of a
cohort of patients in clinical trials that could potentially benefit from immunotherapy
approaches.
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Chapter 1
Background and significance
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Pancreatic cancer – Disease burden and mortality
Pancreatic cancer has surpassed colorectal cancer and is the third leading cause
of cancer related deaths in the USA. Survival remains poor despite advances in surgical
technique and new combination chemotherapies. Over the past 25 years (1992-2017),
while the incidence and death rate of cancers overall have plummeted, pancreatic cancer
continues to be on the rise despite progresses made in early detection and prevention of
pancreatic cancer. While the incidence of cancers overall decreased by 84.5 persons per
100,000, pancreatic cancer incidence has increased by 1.3 persons per 100,000 over 25
years (Fig. 1a). Similarly, the death rate due to cancers overall decreased by 60.9
persons per 100,000, whereas in pancreatic cancers the death rate has marginally
increased by 0.4 persons per 100,000 people during the same period (Fig. 1a).
Pancreatic cancer is usually a disease of the elderly with maximum number of patients
diagnosed between 65-74 years of age, with a median age of 70 years. At diagnosis,
more than half of the patients (52%) have advanced metastatic disease and 30% of
patients have regional spread to lymph nodes (Fig. 1b), indicating the aggressive and
highly metastatic nature of the disease. Therefore, the five- year survival rate in
pancreatic cancer remains at a dismal 10%.
Histologically, the pancreas is composed of an exocrine part with acinar cells
secreting digestive enzymes and an endocrine part which secretes hormones such as
insulin and glucagon. Most of the cancers arise from the exocrine pancreas (nearly
85%)(Hruban and Fukushima, 2007). Pancreatic ductal adenocarcinoma (PDAC)
represent the majority of the tumors arising from the pancreatic acini (Fig. 1c). This is
the form of cancer that is commonly referred to as ‘Pancreatic cancer’ ubiquitously and
henceforth in this manuscript. Other common exocrine pancreatic tumors include, acinar
5

cell carcinomas, colloid carcinomas, serous cystadenomas and undifferentiated
carcinomas(Hruban and Fukushima, 2007). Tumors arising from the pancreatic islets are
referred to as neuro-endocrine tumors, which account for 1-5% of the total pancreatic
neoplasms.
Figure 1
a
Pancreatic cancer

12.5

11.2

11.1

10.7

Overall cancers
503.4
415.5

213.5
152.6

b

c

Pancreatic ductal adenocarcinoma
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Fig. 1: Pancreatic cancer – Disease burden and mortality
(a) Overall cancers Vs. pancreatic cancer incidence and death rate; 25 year statistics.
(b) PDAC disease spread and metastasis at diagnosis. (c) Representative hematoxylin
and eosin (H&E) stained micrograph of PDAC. Fig. 1 - Reproduced with permission from
https://seer.cancer.gov).
Pancreatic cancer – risk factors and disease staging
Among the various known risk factors for PDAC, patients with a known family history of
PDAC with germline mutations such as Familial atypical multiple mole melanoma
(FAMM) and Peutz Jeghers syndrome carry the highest risk for PDAC(Stoffel et al.,
2019) (Fig. 2a). Other familial diseases that increase the risk of PDAC are tabulated in
Fig. 2a. Tobacco use and smoking are associated with a higher risk of PDAC (2.5 to 3.6
times more that in non-smokers)(Ryan et al., 2014, Stoffel et al., 2019). Obesity,
underlying pancreatitis and diabetes mellitus are other important morbidities that are
associated with an increased risk of developing PDAC(Ryan et al., 2014). The other
factors that do not have a clear association with increased risk of developing PDAC
include high-fat diet intake, coffee intake, alcohol consumption, H.pylori and Hepatitis B
infections. According to the modified 8th edition of the American Joint Committee of
Cancer (AJCC), TNM (Tumor-Node-Metastasis) staging classification has staged
pancreatic cancer into four main stages(Allen et al., 2017), based on tumor size,
resectability, loco-regional spread to lymph nodes, superior mesenteric artery or celiac
axis and distant metastasis to the liver or lungs (Fig. 2b-c).
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Figure 2
a

b

c

Stage IA

Stage IB

Stage IIA

Stage IIB

Stage 3

Stage 4

Fig. 2: Pancreatic cancer – risk factors and disease staging
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(a) Genes associated with increased risk for developing PDAC - Reproduced with
permission from (Stoffel EM, McKernin SE, Brand R, Canto M, Goggins M, Moravek C,
et al. Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion.
J Clin Oncol 2019;37(2):153-64 doi 10.1200/JCO.18.01489). (b) AJCC modifed 8th
edition for staging of PDAC – Reproduced with permission from (Allen PJ, Kuk D, Castillo
CF, Basturk O, Wolfgang CL, Cameron JL, et al. Multi-institutional Validation Study of
the American Joint Commission on Cancer (8th Edition) Changes for T and N Staging in
Patients With Pancreatic Adenocarcinoma. Ann Surg 2017;265(1):185-91 doi
10.1097/SLA.0000000000001763). (c) Schematic representation of stages of spread of
PDAC – Reproduced with permission from (https://www.cancerresearchuk.org/aboutcancer/pancreatic-cancer/stages-types-grades/tnm-staging)
Genetic alterations in pancreatic cancer
Sequencing for genetic alterations from TCGA database revealed that PDAC is
invariably associated with mutations in Kras, KrasG12D mutation being the most common
(83% of PDACs, Fig. 3). Other genes in PDAC that are mutated include TP53, SMAD4,
TTN, CDKN2A and MUC16 in decreasing order of their frequencies (Fig. 3). KrasG12D
(Kras* or oncogenic Kras) mutation, which represents the principle driver mutation, is
required for both the initiation and maintenance of PDAC(Collins et al., 2012). Multiple
studies in PDAC have demonstrated that PDAC that developed in the presence of Kras*
regress completely when the oncogenic signal is extinguished, suggesting that Kras* is
critical for the survival of the cancer cells(Collins et al., 2012, Ying et al., 2012). In multiple
murine studies, mutations in tumor suppressors such as TP53, SMAD4 and CDKN2A
have shown to accelerate pancreatic carcinogenesis but were unable to initiate or
maintain tumors in the absence of Kras* (Bardeesy et al., 2006, Hingorani et al., 2005,
Aguirre et al., 2003). Kras* signaling reprograms pancreatic acinar cells into ductal
lineage and progresses through pre-neoplastic and invasive PDAC stages (Bardeesy et
al., 2006, Hingorani et al., 2005, Aguirre et al., 2003). Pancreatic cancer in humans
progresses through two stages; an initial preinvasive phase and subsequently into
invasive PDAC phase. The preinvasive lesions of pancreatic cancer include mucinous
cystic neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs) and
9

pancreatic intraepithelial neoplasia (PanINs). Although Kras* is indispensable for tumor
initiation, tumor latency and differentiation depend on mutations in tumor suppressor
genes, suggesting that the evolution of PDAC is predicated on alterations in signaling
pathways.

10

Figure 2

Figure 3

Fig.3: Principle genetic alterations in pancreatic ductal adenocarcinoma. Analysis of key genetic mutations,
mutational type and significance from https://www.cbioportal.org. Patients from five datasets (Pancreatic ductal
adenocarcinoma – ICGC-Nature 2012, QCMG-Nature 2016, TCGA Firehose Legacy, TCGA PanCancer Atlas and
UTSW-Nat Commun 2015) were analyzed.
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Acinar-Ductal metaplasia and Pancreatic intra-epithelial neoplasia: Pancreatic acini
differentiate into ductal lineage and transform into duct like cells under environmental
and genetic pressures(Takaori et al., 2004). This is a reversible process and the
pancreatic epithelium returns to its normal, functional state when the factors causing
injury to the pancreatic epithelium are removed(Pour et al., 2003). The process where
one epithelial cell type changes to another as an adaptive response to injury is known as
metaplasia. In the pancreas, injury to the pancreatic epithelium usually results from
alcohol intake, smoking, obstruction of the hepato-pancreatic duct due to gallstones, all
of these result in pancreatitis (an inflammatory condition of the pancreatic acini). To
escape, the pancreatic acini differentiate into duct like cells and become resistant to the
agents causing injury, a process known as acinar-ductal metaplasia (ADM)(Pour et al.,
2003). However, in the face of sustained insult to the pancreatic acini, ADM progresses
to pancreatic intra-epithelial neoplasia. Chronic pancreatitis is frequently associated with
ADM and poses a significant risk factor for the development of PDAC(Wei et al., 2016).
Murine pancreatic cancer studies demonstrate that although chronic pancreatitis
accelerates the development of PDAC(Wei et al., 2016), concomitant pancreatitis was
not required for the development of PanINs or PDAC(Habbe et al., 2008). One study that
analyzed the role of inflammation in PDAC demonstrated that in the absence of TP53,
chronic pancreatitis led to development of other lineages of pancreatic tumors such as
acinar cell carcinoma, neuro-endocrine tumors and rarely PDAC(Swidnicka-Siergiejko et
al., 2017).

Current therapies in pancreatic cancer:
Among patients diagnosed with pancreatic cancer, ~20% of the patients are eligible for
surgical resection as many of the patients are at an advanced stage at the time of
12

diagnosis(Kamerkar et al., 2017). The common surgeries for pancreatic cancer include
Whipple procedure (pancreaticoduodenctomy), distal pancreatectomy or complete
pancreatectomy (all of which involve removing some or all portions of the pancreas). In
many cases, pancreatic cancer surgeries are palliative in nature, which relieve symptoms
such as pain, nausea/vomiting and jaundice due to PDAC obstructing the surrounding
structures such as the duodenum or bile duct(Kamerkar et al., 2017). Among the
chemotherapeutic agents used in the treatment of PDAC, 5-Fluorouracil (5-FU) was one
of the early reagents used along with radiation therapy in patients that underwent
resection(Neoptolemos et al., 2004). 5-Fluorouracil as a single agent improved the
overall survival (median) of resected PDAC patients from 15.5 months (No chemotherapy
group) to 20.1 months (with 5-FU) (Fig. 4a) (Neoptolemos et al., 2004). Further studies
in pancreatic cancer demonstrate that in resectable PDAC, Gemcitabine (35 months)
and FOLFIRINOX (54.4 months) (5-FU, Irinotecan, oxaliplatin and folinic acid) remain
the standard for treatment of PDAC (Fig. 4b)(Conroy et al., 2018). In metastatic
pancreatic cancer, Gemcitabine with nab-Paclitaxel improved overall survival of PDAC
by 1.8 months, whereas FOLFIRINOX regimen improved the overall survival by 4.3
months (Fig. 4c-d) (Von Hoff et al., 2013, Conroy et al., 2018, Conroy et al., 2011).
Overall, gemcitabine and FOLFIRINOX regimens only marginally improves survival of
metastatic adenocarcinomas, which constitute the majority of the PDAC (> 52% of
cancers at presentation).
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Figure 4

a

b

Overall survival

Overall survival

5-FU

c
Overall survival

d
Overall survival

Fig. 4: Current therapies in pancreatic cancer. (a-d) Kaplan-Meier survival curves
depicting overall survival of PDAC patients in clinical trials. (a-b) Overall survival of
resectable PDAC patients – Reproduced with permission from (a) (Neoptolemos JP,
Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, et al. A randomized trial of
chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J
Med 2004;350(12):1200-10 doi 10.1056/NEJMoa032295). (b) (Conroy T, Hammel P,
Hebbar M, Ben Abdelghani M, Wei AC, Raoul JL, et al. FOLFIRINOX or Gemcitabine as
Adjuvant Therapy for Pancreatic Cancer. N Engl J Med 2018;379(25):2395-406 doi
10.1056/NEJMoa1809775). (c-d) Overall survival of metastatic PDAC patients –
Reproduced with permission from (c)(Von Hoff DD, Ervin T, Arena FP, Chiorean EG,
Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus
gemcitabine. N Engl J Med 2013;369(18):1691-703 doi 10.1056/NEJMoa1304369). (d)
(Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al.
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med
2011;364(19):1817-25 doi 10.1056/NEJMoa1011923).
T cells and myeloid cells in the pancreatic tumor microenvironment
Checkpoint immunotherapy has revolutionized the treatment of cancers such as
melanoma, bladder cancer and lymphomas(Hodi et al., 2010, Lamm et al., 1991).
However, PDAC remains refractory to checkpoint immunotherapy(Royal et al., 2010, Le
14

et al., 2013), with no survival benefits in clinical trials and pre-clinical animal
models(Winograd et al., 2015). This prompted a comparison of immune infiltrates in the
TME of PDAC and melanoma. One study found that the pancreatic TME had minimal to
moderate infiltration of T cells and that these infiltrates were primarily in the stromal area
and excluded from the tumoral area compared with melanoma, where the T cells were
predominantly in the tumoral area(Blando et al., 2019). Failure to respond to immune
checkpoint blockade has also been attributed to an immunosuppressive tumor
microenvironment (TME), low neo-epitope burden, and lack of tumor infiltrating T cells
resulting from a desmoplastic stroma(Evans et al., 2016, Olive et al., 2009). Although
PDAC is considered an immunologically ‘cold’ tumor with minimal T cell infiltration(Evans
et al., 2016), spatial distribution analyses of T cells within human PDAC tumors reveal
that proximity of CD8+ cytotoxic lymphocytes (CTLs) to the tumor cells correlate with
improved patient survival(Carstens et al., 2017, Blando et al., 2019).
T- cells in PDAC can be broadly divided into either pro-tumorigenic or anti-tumorigenic T
cells based on their functional role in the progression of PDAC. Studies on the role of
innate T cells in PDAC demonstrate that gd T cells support pancreatic oncogenesis and
tumor progression by restraining the adaptive ab T cell response(Daley et al., 2016). The
authors further show that the gd T cells create an immune suppressive TME by
checkpoint receptor (PDL-1) ligation in tumor infiltrating ab T cells(Daley et al., 2016).
Subsequently, a study that explored the role of CD4+ T cells in PDAC initiation
demonstrated that ablation of CD4+ lymphocytes prevents the pancreatic carcinogenesis
in caerulein-induced PDAC models (Fig. 5a)(Zhang et al., 2014, McAllister et al., 2014).
In another study that utilize orthotopic pancreatic cancer model, T regs, a subset of CD4+
T cells have been shown to promote tumor progression by suppressing the function of
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antigen presenting dendritic cells in pancreatic cancer(Jang et al., 2017). While these
studies support a tumor-promoting role of CD4+ and gd T cells in PDAC, ablation of
specific T cell populations in mice also showed to have no impact on PDAC
progression(Evans et al., 2016). The myeloid cells constitute a substantial portion of the
dense, fibrotic stroma in PDAC. Depletion of myeloid cells resulted in an anti-tumor T cell
response and inhibition of pancreatic tumorigenesis (Fig. 5b)(Zhang et al., 2017).
Myeloid cells inhibit cytotoxic lymphocytes by inducing the expression of PD-L1 on
cancer cells thereby masking anti-tumor immune response. Another study specifically
probing the role of myeloid derived suppressor cells (MDSCs) in PDAC demonstrated
that a specific subset of myeloid cells viz. Gr- MDSCs inhibit cytotoxic lymphocytes in
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these

a

mice(Zhang

et

al.,

2017).
Figure 5

b

Fig. 5: T cells and myeloid cells in the pancreatic tumor microenvironment
(a) Schematic indicating the tumor promoting role of CD4+ T lymphocytes in PanIN
lesions. CD4+ T cells inhibit CD8+ T cells, preventing their anti-tumor activity. Depletion
of both CD8+ and CD4+ T cells rescue the tumorigenesis in Kras* driven PDAC model.
Reproduced with permission from (Zhang Y, Yan W, Mathew E, Bednar F, Wan S, Collins
MA, et al. CD4+ T lymphocyte ablation prevents pancreatic carcinogenesis in mice.
Cancer Immunol Res 2014;2(5):423-35 doi 10.1158/2326-6066.CIR-14-0016-T). (b)
Schematic depicting that CD11b+ myeloid cells protect tumour cell viability by inhibiting
CD8+ T-cell mediated anti-tumor immune response in PDAC. Reproduced with
permission from (Zhang Y, Velez-Delgado A, Mathew E, Li D, Mendez FM, Flannagan
K, et al. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the
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establishment of an immunosuppressive environment in pancreatic cancer. Gut
2017;66(1):124-36 doi 10.1136/gutjnl-2016-312078).
Kras* in pancreatic tumor microenvironment
Kras* not only promotes cancer cell survival and proliferation, but also plays an important
role in supporting an immunosuppressive tumor microenvironment (TME)(Zhang et al.,
2014, Zhang et al., 2017, Liao et al., 2019). Murine PDAC models using an inducible
Kras* suggest that activation of Kras* decreases T cells and increases macrophage
infiltration in the tumor microenvironment (Zhang et al., 2014). Therefore, PDAC is
considered an immunologically ‘cold’ tumor with minimal T cell infiltration(Evans et al.,
2016). Another study in a colorectal cancer model with inducible Kras* mutation
demonstrated that Kras*- IRF2 signaling axis promoted a T cell deficient and
myeloproliferative tumor micro-environment. Further, the authors demonstrate that Kras*
inhibition rendered the colorectal cancers sensitive to checkpoint immunotherapy (Liao
et al., 2019). These findings thus support a role for intratumoral T cells in PDAC
progression, and intersection of cancer-cell autonomous programs with compositional
changes of the immune TME may uniquely position PDAC to escape immune
surveillance and response to immune checkpoint therapy. Critical knowledge gaps
persist in our evolving understanding of the complex desmoplastic reaction associated
with PDAC; and the precise role of Kras* in shaping the immune landscape of PDAC
remains elusive. The molecular underpinnings of immunosuppression in PDAC also
remains poorly understood. Deciphering the functional contribution of the immune
microenvironment and the nodes of regulation governing immune infiltration and antitumor immune responses in PDAC is critically needed to impact disease progression.
Kras* targeting using iExosomes:
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Kras* mutation, although ubiquitous in PDAC represents a poorly druggable target(Cox
et al., 2014). Although small molecules have been developed to target the oncogenic
KrasG12C mutation in lung cancers, the KrasG12D mutation has been practically
undruggable(Ostrem et al., 2013). The Kalluri laboratory recently developed a novel
approach to target oncogenic Kras using engineered exosomes (iExosomes) with siRNA
and validated this strategy in multiple preclinical PDAC models(Kamerkar et al., 2017,
Mendt et al., 2018). Exosomes are endogenous membranous vesicles, 50-150 nm in
diameter excreted by all cell types into body fluids and tissues. Their functions include
transfer of molecular cargo, proteins, lipids and nucleic acids, between cells facilitating
long-distance intercellular communication. Efficient siRNA transfer by exosomes(ElAndaloussi et al., 2012) inspired the generation of iExosomes for Kras*-siRNA delivery.
iExosomes combine two important characteristics that enable efficient Kras* targeting.
First, they avoid immune clearance by monocytes as they present “self” CD47 signal
(Kamerkar et al., 2017, Chao et al., 2012), and thereby circumvent antigen presentation
and escape an immune response. Second, the iExosomes strategy exploits
micropinocytosis in Kras* mutant cells that facilitate uptake of exosomes loaded with
Kras*- siRNA into cancer cells (Kamerkar et al., 2017, Commisso et al., 2013). In our
study, we use this treatment modality, that efficiently targets Kras* is used to determine
the effect of distinct T cell subsets on the outcome of Kras*-targeting therapies.
Factors affecting T cell function in the pancreatic tumor microenvironment
i)

Microbiome

The gut microbiome has been implicated as one of the critical modulators of immune
response in multiple cancer models. In melanoma mouse tumor models, it was found
that ablation of the gut microbiome led to deterioration of immune response to checkpoint
immunotherapy (Sivan et al., 2015, Routy et al., 2018). Similar findings were replicated
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in non-small cell lung cancer and sarcoma murine models(Routy et al., 2018). Further
analysis implicated Bifidobacterium as the critical mediator of anti-tumor response in
these studies(Sivan et al., 2015). In melanoma patients, however the response to
checkpoint immunotherapy correlated with presence of Ruminococcaceae bacteria in the
gut microbiome(Gopalakrishnan et al., 2018). Increased alpha diversity, relative
abundance of certain bacterial taxa and presence of T cells in the TME positively
correlated with a response to checkpoint immunotherapy, whereas a lack of diversity in
the microbial flora, antibiotic treatment and T cell deficient TME correlated negatively.
Novel regulatory networks of PDAC immune TME have also implicated the
microbiome. Ablation of the microbiome with broad spectrum antibiotics (Abx) protects
against preinvasive PDAC by reducing myeloid derived suppressor cells (MDSCs), and
increasing M1 macrophages and TH1 differentiation in the pancreas(Pushalkar et al.,
2018). Bacterial ablation using broad spectrum antibiotics also increased efficacy of
checkpoint immunotherapy in an orthotopic KPC model(Pushalkar et al., 2018). A
comparison of microbiome diversity in humans indicated that long term survivors of
PDAC display a high microbial alpha diversity. Human to mice fecal microbiome
transplantation with fecal microbiota from long term survivors suppressed PDAC tumor
growth, showed increased intratumoral CD8+ T lymphocyte, enhanced Granzyme B and
IFN-g expression, and decreased Tregs, MDSCs and IL-2 compared to fecal microbiota
transfer from short term survivors and untreated mice(Riquelme et al., 2019). These
studies also indicate that anti-tumor immune response implicate systemic control exerted
by the gut microbiome. The impact of Kras* in pancreas neoplasia, immune cells and the
microbiome is unknown. To determine if such cooperation exists in PDAC, we utilize
genetically engineered mouse models (GEMMs) with inducible Kras* in a conditional P53
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or Tgfbr2 null background to identify the functional role of Kras* in modulating the
immune TME. This was also studied in the context of a recently developed therapeutic
strategy to target Kras* with exosomes(Kamerkar et al., 2017, Mendt et al., 2018) in
spontaneous PDAC mice with conditional KrasG12D/+ and P53R172H/+ mutations(Hingorani
et al., 2005). Subsequently, we analyze the impact of the gut microbiome on T cell
responses using orthotopic implanted tumors in GEMMs with depletion of specific T cell
populations.
ii)

Pancreatitis

Frequently, patients with pancreatic cancer develop bile duct obstruction due to
tumors impinging on the bile duct leading to chronic pancreatitis. In the clinical setting,
chronic pancreatitis is usually a result of multiple acute insults to the pancreas. In
addition, radiation and chemotherapeutic agents are known to induce pancreatitis in
PDAC patients(Stromnes et al., 2014). However, chronic pancreatitis by itself was
insufficient to induce PDAC(Swidnicka-Siergiejko et al., 2017). In pancreas specific Kras
mutant mice, pancreatitis has shown to accelerate pancreatic tumorigenesis. Although
pancreatitis has been associated with an increased risk of PDAC, the causal link remains
weak. Several studies indicate that Treg and TH17 subsets of CD4+T cells promote
pancreatic tumorigenesis in PDAC models in a background of pancreatitis(Zhang et al.,
2014, McAllister et al., 2014). However, depletion of CD4 and CD8+ T cells in a
spontaneously developing PDAC model did not result in any difference in tumorigenesis
and survival. The precise changes that underlying pancreatitis induce in the tumor
microenvironment remains unclear. Understanding the differences in the biology of
spontaneously developing PDAC and PDAC developing in a setting of chronic
pancreatitis are critical if we are to unleash the immune system to treat PDAC associated
with pancreatitis.
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In this study, we first determine how Kras* modulates the immune microenvironment
using a pancreas specific inducible Kras* allele in a P53 or Tgfbr2 mutant background.
We identify the critical nodes of immune regulation in PDAC that are controlled by Kras*
in the TME. Subsequently, we deplete these specific immune populations in the context
of Kras* targeting therapy to understand the relevance of combining Kras* and T cell
targeting therapies. In the second part of my project, we probe the functional differences
in the immune microenvironment of spontaneously progressing PDAC and PDAC in the
context of underlying pancreatitis. We analyze how the presence of inflammation
transforms the fundamental nature of tumor microenvironment and explore potential
ways to exploit the inflammatory TME to treat pancreatic cancer.
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Chapter 2
Material and methods
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Animal studies
i)

PiKP and PiKT mice
The genotyping and tumor kinetics of the Ptf1αcre/+, tetO/CMV-LSL_KrasG12D/+,

P53f/f, LSL-rtTA-EGFP (PiKP) model used in this study has been described
previously(Ying et al., 2012). To generate Ptf1αcre/+, tetO/CMV-LSL_KrasG12D/+, Tgfbr2f/f,
LSL-rtTA-EGFP (PiKT) model, P53f/f allele was bred out of the PiKP colony and replaced
with Tgfbr2f/f mice (Chytil et al., 2002). Schematic of the mouse genetics is shown in (R
Fig. 1a). For Kras* induction, mice were fed Doxycycline (Dox) water (Dox 2g/L, sucrose
20 g/L) starting at 18 weeks of age. ‘Kras* On’ cohort mice were maintained on Dox water
until they were euthanized when mice reached moribundcy. Mice in the ‘Kras* off’ cohort
were maintained on Dox until tumors had progressed to advanced stage (on average 6
weeks), following which mice were fed regular water without Dox and euthanized at 5
days, 2 weeks, 4 weeks or ≥21 weeks after Dox withdrawal.

ii)

KPC CD4-/- and KPC CD8-/- mice
Pdx1-Cre; LSL-KrasG12D/+; P53R172H/+ (referred to as KPC) mice have been

described previously(Hingorani et al., 2005). These mice were bred to CD4-/- (Cd4tm1Mak)
and CD8-/- (Cd8tm1Mak) mice (both kindly provided by Dr. Tak Mak, University Health
Network- University of Toronto) to obtain KC, KC CD4-/-, KC CD8-/-, KPC, KPC CD4-/- and
KPC CD8-/- mice. All these mice were interbred and maintained on FVB/ C57Bl6/ BALB/c
mixed background. iExo treatment was started on at 14 weeks following baseline MRI
measurements in KPC, KPC CD4-/- and KPC CD8-/- tumor bearing mice as described
earlier. GMP-compliant iExosomes from bone marrow derived mesenchymal stem cells,
electroporated with siKras* were used as previously described in (Mendt et al., 2018).
MRI imaging was performed using Bruker 7.0T MRI prior to start of iexosome therapy
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and 2 and 4 weeks post start of iExosomes therapy. iExosomes were injected intraperitoneal (i.p.) every 48 hours following baseline MRI till the endpoint or moribundcy in
these mice as described earlier(Kamerkar et al., 2017).
We use an analogue of cholecystokinin (caerulein) to induce pancreatitis in mice.
Caerulein treatment (individual dose: 50 µg/ Kg, i.p.) was started at 6 weeks of age in
KC, KC CD4-/- and KC CD8-/- mice to induce acute or chronic pancreatitis. For acute
pancreatitis experiments, the mice were given 6 hourly caerulein injections (4 times a
day) on two alternative days, 24 hours apart (Zhang et al., 2014). The acute pancreatitis
mice were sacrificed for histology and tumor comparisons 21 days following the start of
caerulein injections. For chronic pancreatitis experiments, the mice were similarly
injected 3 times a week for 3 consecutive weeks as described earlier(McAllister et al.,
2014). Blood was collected by retro-orbital bleeding (50 µL each time) on days 3, 12, 18
and 22 for measurement of pancreatic enzymes. The chronic pancreatitis mice were
sacrificed on day 53 following start of caerulein injections as described earlier(McAllister
et al., 2014). For checkpoint blockade, an initial 200 μg αCTLA-4 (BioXCell, clone 9H10,
BE0131), αPD-1 (RMP1-14, BE0146) antibody followed by two injection of 100 μg of
αCTLA-4, αPD-1 antibodies were administered i.p.. For depletion of dendritic cells, four
doses of 500 μg of anti-mouse CD11c (ThermoFischer scientific, Clone N418, C11538)
were administered 5 days apart. Corresponding isotype controls - Syrian Hamster IgG
(BioXcell, BE0087), Rat IgG2a (BioXcell, clone 2A3, BE0089) and Armenian hamster
IgG (BioXcell, BE0091) were administered in the same route, dose and frequency as the
antibody.
iii)

Microbiome experiments:
For microbiome studies, 8-16 weeks old C57Bl6 mice and CD4-/- (bred in C57Bl6
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background) were co-housed for 2 weeks and subsequently given 2 treatments of fecal
microbiota transplant (FMT) 1 week apart. For microbiome ablation, these mice were
treated with broad spectrum antibiotics by oral gavage three days a week (2 doses, 12h
apart each day). The oral gavage contained an antibiotic cocktail with vancomycin (50
mg/mL; Sigma-Aldrich), neomycin (10 mg/mL; Sigma-Aldrich), metronidazole (100
mg/mL; Santa Cruz Biotech), and amphotericin (1 mg/mL; MP Biomedicals). In addition,
ampicillin (1 mg/mL; Santa Cruz Biotech) was added to drinking water of mice. Under
general anesthesia, 1 x 106 KPC 689 cells (with GFP-Luc) were injected orthotopically
into the pancreas of mice using Hamilton 81000 syringe. Measurements for radiance
(photons s−1 cm−2 sr−1) were obtained by IVIS imaging (Xenogen spectrum) under
uniform conditions across all experimental groups. iExo treatment was started on day14
following baseline IVIS imaging in KPC 689 orthotopic tumor bearing mice as described
earlier(Kamerkar et al., 2017). All the mice were housed in MDACC animal facility under
pathogen-free conditions and animal procedures were approved by MDACC institutional
animal care and use committee.

Tissue processing
Blood was collected via retro-orbital vein and transferred into EDTA-tubes (BD
365974). Tumor, healthy pancreas, spleen and mesenteric lymph node were collected
and placed into RPMI (Corning™, 10041CM) with 10% fetal bovine serum (FBS) on ice.
The tumor was divided in three parts: one part of tumor was embedded in OCT
compound, one part was formalin-fixed for histological analysis, and one part was
processed for immunotyping or T cell isolation.

Immunotyping
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Single cell suspensions were prepared from tumor, spleen and lymph node. Tumors were
minced and digested in 5-10 mL of 0.1 mg/mL Liberase TL (Roche, 05401020001) and
0.2 mg/mL DNaseI (Roche, 10104159001) in RPMI-1640 for 30 min at 37 °C with gentle
mixing. The digestion was stopped with equal volume of stop mixture (RPMI-1640, 10%
FBS, 10 mM EDTA). Cells were filtered through 100 μm cell strainer (Corning 352350),
washed 3 times with FACS buffer (PBS, 2% FBS). Spleens and lymph nodes were
mashed through 100-um cell strainer and washed once with FACS buffer. Subsequently,
ACK Lysing Buffer (Quality Biological, 118-156-101) was added to blood to lyse red blood
cells. After a 5 min incubation at RT, the cell pellet was washed twice with PBS. Cells
were stained with 100-μL surface antibody cocktail diluted in [FACS buffer, 20% Brilliant
Stain Buffer (BD Bioscience, 566349), 50 μg/mL anti-mouse CD16/CD32 (2.4G2) block
(TONBO biosciences, 40-0161), Fixable Viability Dye eFluor780 (eBioscience, 65-086514)] for 30 min on ice. Cells were washed twice with FACS buffer, fixed-permeabilized
with Foxp3/Transcription Factor Staining Buffer Set (eBioscience, 00-5523-00) and
stained for 30 min with intracellular antibody cocktail diluted in Fixation/Permeabilization
diluent

(eBioscience,

00-5223)

on

ice.

Cells

were

washed

twice

with

Fixation/Permeabilization diluent, fixed in Fixation buffer (BD Bioscience 554655), and
washed with FACS buffer. Antibodies used in surface and intracellular staining cocktails
are described in Table 1a. Data were acquired on Fortessa-X20 (BD Bioscience) and
analyzed with FlowJo V10. Immune populations were gated on single live CD45+ cells.
Different immune cell populations were determined using gating strategies shown in
Table 1b.
Table 1a. Antibodies used for flow cytometry
Antibody

Surface/

Dilution

Vendor, catalogue #
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Intracellula
r
Anti-mouse CD45-Pacific Blue
(Clone 30-F11)
Anti-mouse CD45-PE-Cy7 (Clone
30-F11)
Anti-mouse CD3-PE-Cy7 (Clone
145-2C11)
Anti-mouse CD3-Alexa700 (Clone
17A2)
Anti-mouse CD4-BV605 (Clone
RM4-5)
Anti-mouse CD8-BV650 (Clone 536.7)
Anti-mouse CD11b-BV711 (Clone
M1/70)
Anti-mouse CD11b-BV786 (Clone
M1/70)
Anti-mouse PD1 PerCP-Cy5.5
(Clone 29F.1A12)
Anti-mouse PDL1-APC (Clone
F.9G2)
Anti-mouse PDL1- PE (Clone MIH5)
Anti-mouse CD49b-PE (Clone Dx5)
Anti-mouse NK1.1 (Clone PK136)
Anti-mouse Ki67-Alexa 488 (Clone
B56)
Anti-mouse FoxP3 (Clone FJK-16s)
Anti-mouse F4/80-PE (Clone Cl:A31)
Anti-mouse Ly6C-APC (Clone AL21)
Anti-mouse Ly6G-PE-Cy7 (Clone
1A8)
Anti-mouse CD19-BV650 (Clone
6D5)
Anti-mouse CD19-PerCP-Cy5.5
(Clone 1D3)
Anti-mouse CD11c-eFluor615
(Clone N418)

Surface

1:100

Bio Legend, 103126

Surface

1:200

BD Bioscience, 552848

Intracellular

1:200

eBioscience, 25-0031-82

Intracellular

1:50

eBioscience, 56-0032-82

Surface

1:200

BioLegend, 100548

Surface

1:200

BioLegend, 100742

Surface

1:400

BD Bioscience, 563168

Surface

1:100

BD Bioscience, 740861

Surface

1:100

BioLegend, 135208

Surface

1:100

BioLegend, 124312

Surface
Surface
Surface

1:100
1:100
1:200

eBioscience, 12-5982-83
eBioscience, 12-5971-81
eBioscience, 12-5941-83

Intracellular

1:100

BD Bioscience, 558616

Intracellular

1:50

eBioscience, 56-5773-82

Surface

1:10

BioRad, MCA497PE

Surface

1:200

BD Bioscience, 560595

Surface

1:200

BD Bioscience, 560601

Surface

1:100

BioLegend, 115541

Surface

1:100

BD Bioscience, 561113

Surface

1:50

eBioscience, 42-0114-82
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Anti-mouse CD11c-PE-CF594
(Clone HL3)
Anti-mouse MHCII eFluor450
(Clone M5/114.15.2)
Anti-mouse MHCII-BV510 (Clone
M5/114.15.2)
Anti-mouse CD40-BV650 (Clone
3/23 )
Anti-mouse CD86-BV605 (Clone
GL1)
Anti-mouse CD45RB-APC (Clone
C363.16A)
Anti-mouse CD45RB-FITC (Clone
C363.16A)
Anti-mouse TIM3-PE/Dizzle (Clone
B8.2C12)
Anti-mouse TIM3-BV711 (Clone
RMT3-23)
Anti-mouse T-bet-PE-Cy7 (Clone
eBio4B10)
Anti-mouse GranzB-APC (Clone
GB11)
Anti-mouse CD44-PE-Cy7 (Clone
IM7)
Anti-mouse CD62L-APC (Clone
MEL-14)
Anti-mouse CD25-APC-Cy7 (Clone
PC61)
Anti-mouse CD25-APC_R700
(Clone PC61)
Anti-mouse CD69-PE-CF594
(Clone H1.2F3)

Surface

1:100

BD Bioscience, 562454

Surface

1: 300

eBioscience, 48-5321-80

Surface

1:100

BioLegend, 107635

Surface

1:100

BD Bioscience, 740492

Surface

1:100

BD Bioscience, 563055

Surface

1:100

eBioscience, 17-0455-81

Surface

1:100

eBioscience, 11-0455-82

Surface

1:100

BioLegend, 134013

Surface

1:100

eBioscience, 119727

Intracellular

1:100

eBioscience, 25-5825-80

Intracellular

1:100

Invitrogen, GRB05

Surface

1:100

BD Bioscience, 560569

Surface

1:100

BD Bioscience, 561919

Surface

1:100

BD Bioscience, 561038

Surface

1:100

BD Bioscience, 565135

Surface

1:100

BD Bioscience, 562455

Table 1b. Phenotyping of cells in flow cytometry analysis
Cell
T cells
CD4+ T cell
CD8+ T cell
Treg
Myeloid cells

Phenotype
Live/CD45+/CD3+
Live/CD45+/CD3+/CD4+
Live/CD45+/CD3+/CD8+
Live/CD45+/CD3+/CD4+/FoxP3+
Live/CD45+/CD11b+
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Mo-MDSC
Gr-MDSC
Ly6C- Ly6GB cells
NK cells

Live/CD45+/CD11b+/Ly6C+/ Ly6G low/Live/CD45+/CD11b+/Ly6G+/Ly6C low/Live/CD45+/CD11b+/Ly6C-Ly6GLive/CD45+/CD19+
Live/CD45+/CD3-/NK1.1+ or
Live/CD45+/CD3-/CD49b+

Immunofluorescence
Immunofluorescence staining was performed using
Tyramide Signal Amplification (TSA) technology as described earlier (Carstens et al.,
2017). In short, 5µm formalin fixed paraffin embedded (FFPE) sections were
deparaffinized and fixed in formaldehyde: methanol (1: 10). Antigen retrieval was
performed in Tris-EDTA (TE) buffer (pH 9.0) at 950C for 15 min, following which the
slides were blocked in 4% Cold water fish gelatin (CWFG) (Sigma-Aldrich, GL7765) for
10 min, stained with primary antibody (1h at RT) and secondary antibody (10 min at
RT), followed by incubation with TSA fluorophore (10 min at RT). In between steps,
tissues were washed with tris buffered saline with 0.1% tween-20 (TBST) 3 times x 2
min each wash. Subsequently, another round of antigen retrieval is performed and the
staining for the next antibody ensues. The details of antibodies, dilution, vendor
information, TSA reagents, polymers and buffers used are detailed in Table 2a. After
the last round of antigen retrieval, slides were cover slipped with mounting media
containing DAPI (FluoroshieldTM with DAPI – F6057). The phenotyping of cells for CD4,
CD8, Foxp3 and CD11b staining in PiKP and PiKT tumors were performed as
described in Table 2b. Multiple representative images (at 20X magnification) were
obtained from the tumor containing areas in the PiKP (Kras* On, Kras* 5d off, Kras* 2w
off and Kras* 4w off) and PiKT mice (Kras* On, Kras* 2w off and Kras*4w off).
Uninvolved pancreatic tissue, associated adipose tissue and intra tumor lymphoid
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follicle were not included for the analysis. Number of CD4+, CD8+, CD11b+, CD4+
Foxp3+ and CD4+ Foxp3- per 20x field were counted and the mean number of each cell
type was tabulated. The average numbers of each of these cell types were compared
between groups.
For the thymus and spleens of KPC, KPC CD4-/- and
KPC CD8-/- mice, 5µm cryostat OCT sections were fixed in acetone at 40 C for 5 min,
blocked in 1% BSA in PBS for 30 mins, stained with primary antibodies - CD4 (Abcam,
Ab183685, 1:400) or CD8 (Abdserotec, MCA1767T, 1:100) in 1% BSA in PBS (1h at
RT) and secondary antibodies (Goat anti-rabbit (H+L), Alexa Fluor Plus 488,
ThermoFischer, A32731, 1:250 for CD4 primary or Goat anti-rat IgG (H+L), Alexa Fluor
400, 1:250 for CD8 primary) (30 min at RT). Subsequently, slides were cover slipped as
described earlier.

Table 2a. T cell panel TSA staining
Antigen
CD8

Primary antibody
Catalogue
Vendor
#
Cell signaling
98941s
technology

CD4

Abcam

Ab183685

Foxp3

ThermoFischer
Scientific

14-477180

CD11b

Abcam

Ab133357

GATA3

Cell signaling
technology

5852S

Rorgt

Abcam

Ab207082

T-bet

Abcam

Ab91109

Secondary antibody
Conc.
1:250
1:400
1:50
1:500
1:1500
1:1000
1:100

Vendor
BioCare
BioCare
BioCare
BioCare
BioCare
BioCare
Vector
Laborotaries

Polymer
Rabbit-on-Rodent
HRP
Rabbit-on-Rodent
HRP
Rat HRP
Rabbit-on-Rodent
HRP
Rabbit-on-Rodent
HRP
Rabbit-on-Rodent
HRP
M.O.M.
Immunodetection kit

TSA
fluorophor
e
Opal 650
Opal 520
Opal 650
Opal 650
Opal 650
Opal 650
Opal 650
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Table 2b. Phenotyping of cells in TSA analysis
Cell type
CD8+ T cells
CD4+ T cells
Treg
Teff
Myeloid cells
T H1
T H2
TH17

Phenotype
CD8+
CD4+
CD4+ Foxp3+
CD4+ Foxp3CD11b+
CD4+ T-bet+
CD4+ GATA3+
CD4+ Rorgt +

Immunohistochemistry
FFPE sections were deparaffinized, antigen retrieval was performed in the
respective buffers mentioned in Table 3 for 15 min at 950 C, endogenous peroxide was
neutralized by treatment with 3% H202 in PBS for 15 min at RT. Subsequently, 4%
CWFG in phosphate buffered saline, 0.1% Tween-20 (PBST) was used for blocking
and staining with primary antibodies listed below (1h at RT), followed by incubation with
secondary antibody (Horse Anti-Rabbit IgG Antibody (H+L), Biotinylated, BA-1100, 1:
200, 1h at RT). Next, the slides were stained using Vectastatin ABC kit, PK 6100 as per
the manufacturer’s instructions. The sections were incubated in DAB and counterstained with hematoxylin. In between steps, tissues were washed with PBST 3 times x
2 min each wash. The buffers used, the antibodies with dilution and vendor information
for IHC are tabulated in Table 3. For analysis of IHC, multiple random images (at 40x
magnification) were selected for scoring CD4+, CD8+ T cells. We observed that majority
of the pancreatic tumor tissue did not show any CD4+ or CD8+ T cells. The
corresponding spleen tissue was used as controls for staining. On average, one in
every 10 fields (40x) had positive staining for CD4+ and CD8+ T cells. Representative
images containing positive staining were quantified and the mean number of each cell
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type was tabulated. The average number of CD4+ and CD8+ T cells were compared
between groups.
For analysis of IHC, multiple random images (at 40x magnification) were
selected for scoring CD4+, CD8+ T cells. We observed that majority of the pancreatic
tumor tissue did not show any CD4+ or CD8+ T cells. The corresponding spleen tissue
was used as controls for staining. On average, one in every 10 fields (40x) had
positive staining for CD4+ and CD8+ T cells. Representative images containing positive
staining were quantified and the mean number of each cell type was tabulated. The
average number of CD4+ and CD8+ T cells were compared between groups. Ki67
proliferation index was calculated on multiple random images from tumors using the
formula: number of Ki67 positive nuclei divided by total number of nuclei in a given
field of vision. Human tonsil tissue was used as positive control for Ki67 staining. For
quantification of CD11b and CD11c staining, total number of positive staining cells per
HPF were calculated from all the PanIN containing area in different groups. For
quantification of CK19, images that cover the whole of PanIN and uninvolved
pancreatic tissue were obtained at low power magnification (10x). Images were
uploaded to Image J software and RGB stack images were obtained. Average
percentage of CK19+ area per 10x field was calculated in the total pancreas.
Table3. Immunohistochemistry
Antigen
CD8
CD4

Antigen retrieval
buffer
TE, pH 9.0

Ki67

TE, pH 9.0
TE, pH 9.0

CD11b
CK19

Citrate, pH 6.0
Citrate, pH 6.0

Vendor
Cell signaling
technology
Abcam

Primary antibody
Catalogue #
98941s
Ab183685

Conc.
1:250

Abcam

Ab15580

1:400
1:100

Abcam
Abcam

Ab133357
Ab52625

1:500
1:200
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CD11c

Citrate, pH 6.0

Cell signaling
technology

97585

1:300

Cell lines
KPC-689 cells (with GFP-Luc) used for orthotopic injections were cultured and
maintained in RPMI-1640 (Corning 10-040-CV) with 10% FBS (Gemini Fetal Plex 100602) and Penicillin-Streptomycin (Corning 30-002-Cl).

Pancreatic enzyme assays
Pancreatic amylase and lipase in the plasma (Blood collected with Heparin
sodium, Sigma-Aldrich, 2106-10VL) were measured by - Section of Veterinary
Laboratory Medicine, DVMS, MD Anderson cancer center. For measurement of fecal
elastase, fresh fecal samples were collected, weighed using pre-weighted barcoded
tubes and processed by manual disruption in the assay buffer recommended. Fecal
elastase measurements (Enzchek, ThermoFischer) were performed as per the vendor’s
instructions.

16S rRNA gene sequencing and bioinformatics analysis
Fecal pellets from mice with and without treatment with broad spectrum antibiotics
were snap frozen. Briefly, the bacterial genomic DNA was extracted from fecal pellets
using QIAamp fast DNA stool kit (Qiagen), with the addition of an intensive bead-beating
lysis step. The V4 hypervariable region of 16S rRNA was amplified and sequenced with
a 2 x 250 bp paired-end protocol on the Illumina Miseq platform, as described earlier
(Shono et al., 2016, Caporaso et al., 2012). Sequencing data from the paired-end reads
were de-multiplexed by QIIME. All identified operational taxonomic units (OUTs) were
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assigned using Mothur method with the Silva database. The relative abundance of each
OTU was determined for all samples. The detailed pipeline of analysis has been
previously described (Wang et al., 2018). For 16S rRNA qPCR, copy numbers of 16S
rRNA was estimated with the following primers – 16S rRNA Forward: 5′-ACT CCT ACG
GGA GGC AGC AGT-3′ AND Reverse: 5′-TAT TAC CGC GGC TGC TGG C −3′.

Statistics
Statistical tests were performed using GraphPad Prism 8 and reported alongside
figure legends. Shapiro- Wilk test was used to assess normality of distribution of
samples to select the statistical test for comparison of means and variance. For
samples with normal distribution, parametric, unpaired T-test and one-way ANOVA
were used for comparison of means and variance respectively. For non-normal
distribution of samples, non-parametric T-test (Mann- Whitney test) and Kruskal-Wallis
test were used. Log-rank test was used to compare Kaplan-Meier survival curves. P
values are reported as *P<0.05, **P<0.01, ***P<0.001, **** P<0.0001, ns: not
significant.
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Chapters 3 – 7: Results
PiKP and PiKT GEM models and immunotyping results experiments described from R.
Fig1-4 in this manuscript were generated by Dr. Elena Ramirez (LeBleu & Kalluri lab)
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Chapter 3: Kras* drives a T cell deficient and myeloproliferative PDAC TME.
i)

Kras* is required for progression and maintenance of PDAC tumors
To analyze the effects of Kras* in shaping the TME, we utilize inducible Kras

mice on conditional TP53 or Tgfbr2 null backgrounds, by generating the PiKP (P48Cre; R26-rtTa-IRES-EGFP; tetO-LSL-KrasG12D/+; P53L/L) and PiKT (P48-Cre; R26-rtTaIRES-EGFP; tetO-LSL-KrasG12D/+; Tgfbr2L/L) genetically engineered mouse models
(GEMMs) (R Fig. 1a). In both GEMMs, Kras* induction by continuous doxycycline
(Dox) administration in the drinking water starting at 18 weeks of age resulted in rapid
development of pancreatic tumors, with similar median survival of ~7 weeks following
Dox administration (R Fig. 1b–c). We also evaluated disease progression in a distinct
cohort of mice wherein Dox was administered to 18 weeks old PiKP and PiKT mice
(activating Kras*), and subsequently withdrawn 6 weeks later (R Fig.1b). Both PiKP
and PiKT mice show a complete regression of tumors following Kras* extinction, and
cancer regression translated into long term survival following Kras* suppression (R Fig.
1d–e).
Next, to understand the effects of Kras* suppression in the TME, we evaluated
the immune composition of PDAC tumors with Kras* and compared it to PDAC tumors
in which Kras* expression was suppressed. We employed the previously described ‘on
and off’ doxycycline-inducible Kras* genetic system(Ying et al., 2012). At the time of Dox
withdrawal, all mice presented with significant, palpable tumors. These mice were
euthanized at 5 days, 4 weeks, and >21 weeks following Dox withdrawal, effectively
evaluating tumors at multiple time points following Kras* suppression (R Fig. 2a).
Histological analysis of the pancreas tissue revealed that healthy pancreatic acini is
replaced by invasive PDAC when mice were on Dox, as previously reported(Ying et al.,
2012). When Dox was withdrawn from mice on Dox, invasive PDAC was replaced by
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normal pancreatic tissue, decrease in tumor weights, PanIN lesions, ADMs (Acinarductal metaplasia), adipose and fibrotic tissue after 4 weeks and 21 weeks of Kras*
ablation (R Fig. 2b–g). Although no changes in tumor histology were observed
immediately after 5days of Dox withdrawal, complete suppression of invasive PDAC was
observed at later time points. Interestingly, much of the invasive PDAC tissue was
replaced with adipose tissue in mice that were off Dox for 4 and 21 weeks (R Fig. 2b).
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R Fig. 1: Kras* is required for progression and maintenance of PDAC tumors
(a) Genotypes of PiKT and PiKP mouse models: Cre-mediated recombination enables
pancreas specific homozygous loss of Tgfbr2 (PiKT) or p53 (PiKP) and rtTA/tetO
controlled KrasG12D (Kras*) expression and extinction (Kras*off). Kras* expression is
induced in the pancreas with Doxycycline (Dox) administration in the drinking water
(Kras* on). Once tumors are formed, Kras* expression is extinguished with withdrawal of
Dox (Kras* off). (b) Timeline of the experiment. Kras* was induced in PiKP and PiKT
mice starting at 18 weeks of age. In one cohort of mice, Kras* was turned off after 6
weeks. The other cohort was Kras* on until end point. (c) Kaplan Meier survival curves
of PiKT and PiKP mice on Dox. PiKT (n=87), PiKP (n=35) mice. (d, e) Kaplan Meier
survival curves of PiKT and PiKP mice with Kras* on and Kras* off after 6 weeks of Kras*
induction with Dox. PiKP Kras* On (n=35), PiKP Kras* On and Off (n=15). PiKT Kras*
On (n=87), PiKT Kras* On and Off (n=30). Significance was determined by log rank test,
***P<0.001, **** P < 0.0001, ns: not significant. This work was done with the help and
collaboration of Dr. Elena Ramirez.
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R Fig. 2: Histopathology of PiKT and PiKP GEMMs
(a) Timeline of the experiment. Kras* was induced in PiKP and PiKT mice at 18 weeks
of age. After 6 weeks of induction, Kras* was turned off and tumors were analyzed at 5
days, 4 weeks and ≥ 21 weeks. (b) Histopathological analyses of H&E pancreas sections
of mice in the indicated groups and time points described in (a). (c) Pancreas or tumor
weights of PiKP and PiKT mice at different time points mentioned in (a). (d, e) Percentage
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of PDAC out of affected pancreas, percentage of affected exocrine pancreatic acini,
score of desmoplasia (active fibrosis) and chronic fibrosis of PiKP (c) and PiKT (d)
tumors. (f, g) Percent of mice with PanIN 1A, PanIN 1B, PanIN2, PanIN3 lesions and
PDAC in Kras* On, 5d off, 4w off and 21w off PiKP (f), and PiKT (g) mice. In (b-g) PiKT:
healthy (n=14), Kras* on (n=16), Kras* 5d off (n=5), Kras* 4w off (n=10), Kras* ≥21w off
(n=15). PiKP: healthy (n=13), Kras* on (n=16), Kras* 5d off (n=3), Kras* 4w off (n=11),
Kras* ≥21w off (n=11) mice. Data are presented as the mean ± SD. Significance was
determined by Unpaired T-test (parametric or non-parametric) in (c) and using KruskalWallis test in (d and e). *P<0.05, **P<0.01, ***P<0.001, **** P<0.0001, ns: not significant.
This work was done with the help and collaboration of Dr. Elena Ramirez.
ii)

Kras* represses T cells and promotes myeloid infiltration in PiKP
tumors
To determine the functional contribution of Kras* in modulating the immune

infiltrates in the PDAC TME, we performed comprehensive flow cytometry
immunophenotyping analyses of the tumors of PikP mice on Dox (on) and 5 days
following Kras* suppression (5d off). The immunophenotyping analysis demonstrated
that Kras* suppression resulted in an increase in the fraction of T cells and a decrease
in the fraction of myeloid cells (R Fig. 3a-c). Subtyping analyses indicated a significant
increase in T cell fractions [T cells (CD3+), Treg (CD4+ Foxp3+), Teff (CD4+ Foxp3-)] in
the PiKP tumors following Kras* suppression (R Fig. 3b-c). The changes in the
frequencies of T cells and myeloid cells in Kras* mice were not as pronounced in the
spleen of these mice (R Fig. 3c), supporting that the impact of suppressing Kras* was
mostly realized in the tumor immune microenvironment. In addition to the increase in T
cell frequencies following Kras* suppression, tumors were also immunolabeled for
immune markers, and quantitative analyses revealed an influx of Treg, Teff, and CD8+ T
cells in Kras* suppressed tumors (R Fig. 3d). A decrease in myeloid immune infiltration
was also observed after 2 weeks of Kras* suppression (R Fig. 3d).
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R Fig. 3: Kras* represses T cells and promotes myeloid infiltration in PiKP tumors.
(a) Intra-tumoral immune composition of PiKP mice with ‘Kras* on’ (n=11 mice) and
‘Kras* 5 days off’ (n=7 mice) determined as % of CD45+ cells by flow cytometry. (b)
Quantification of tumor infiltrating CD45+ cells in ‘Kras* on’ and ‘Kras 5 days off’ mice
analyzed by FlowJo. Cell populations were defined as T cells (CD45+ CD3+), CD4+ T
cells (CD45+ CD3+ CD4+), CD8+ T cells (CD45+ CD3+ CD8+), Treg (CD4+ Foxp3+), Teff
(CD4+ Foxp3-), myeloid cells (CD45+ CD11b+), Gr-MDSC (CD11b+ Ly6G+) and MoMDSC (CD11b+ Ly6C+) populations in PiKP tumors. (c) Fold change of immune cells in
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Kras* 5 days off mice in PiKP tumors and spleens, increase or decrease is indicated by
arrows. (d) Immunolabeling and quantification of CD4+ T cells (CD4), CD8+ T cells (CD8),
myeloid cells (CD11b), Tregs (CD4+ Foxp3+) and Teff (CD4+ Foxp3-) in Kras* On and
Kras* off (5 days, 2 weeks and 4 weeks) PiKP mice (n = 3-6). Scale bars, 100μm. In (b)
and (d), data are presented as the mean ± SD. Significance was determined by Unpaired
T-test (parametric or non-parametric). *P<0.05, **P<0.01, ***P<0.001, **** P<0.0001, ns:
not significant. This work was done with the help and collaboration of Dr. Elena Ramirez.
iii)

Kras* represses T cells and promotes myeloid infiltration in PiKT tumors
To confirm that our findings from our PiKP model was Kras* driven and were not

influenced by the interposition of TP53 mutation in our model, we analyze the effects of
Kras* suppression in a second PiKT model. We performed comprehensive flow
cytometry immunophenotyping analyses of the tumors of PikT mice on Dox (on) and 5
days following Kras* suppression (5d off). The immunophenotyping analysis
demonstrated that Kras* suppression resulted in an increase in the fraction of T cells and
a decrease in the fraction of myeloid cells (R Fig. 4a-c). Subtyping analyses indicated a
significant increase in T cell fractions [T cells (CD3+), Treg (CD4+ Foxp3+), Teff (CD4+
Foxp3-) in the PiKT tumors following Kras* suppression (R Fig. 4b-c). The changes in
the frequencies of T cells and myeloid cells in Kras* mice were not as pronounced in the
spleen of these mice (R Fig. 4c), supporting that the impact of suppressing Kras* was
mostly realized in the tumor immune microenvironment. In addition to the increase in T
cell frequencies following Kras* suppression, tumors were also immunolabeled for
immune markers, and quantitative analyses revealed an influx of Treg, Teff, and CD8+ T
cells in Kras* suppressed tumors (R Fig. 4d). A decrease in myeloid immune infiltration
was also observed after 2 weeks of Kras* suppression (R Fig. 4d). The phenotype in the
PiKT mice almost mirrored that of the PiKP mice following Kras* suppression indicating
firmly that Kras* promotes the exclusion of T cells in PDAC tumors, and favors myeloid
cells infiltration.
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R Fig. 4: Kras* represses T cells and promotes myeloid infiltration in PiKT tumors:
a) Intra-tumoral immune composition of PiKT mice with ‘Kras* on’ (n=11 mice) and ‘Kras*
5 days off’ (n=7 mice) determined as % of CD45+ cells by flow cytometry. (b)
Quantification of tumor infiltrating CD45+ cells in ‘Kras* on’ and ‘Kras 5 days off’ mice
analyzed by FlowJo. Cell populations were defined as T cells (CD45+ CD3+), CD4+ T
cells (CD45+ CD3+ CD4+), CD8+ T cells (CD45+ CD3+ CD8+), Treg (CD4+ Foxp3+), Teff
(CD4+ Foxp3-), myeloid cells (CD45+ CD11b+), Gr-MDSC (CD11b+ Ly6G+) and MoMDSC (CD11b+ Ly6C+) populations in PiKT tumors. (c) Fold change of immune cells in
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Kras* 5 days off mice in PiKT tumors and spleens, increase or decrease is indicated by
arrows. (d) Immunolabeling for CD4+ T cells (CD4), CD8+ T cells (CD8), myeloid cells
(CD11b), Tregs (CD4+ Foxp3+) and Teff (CD4+ Foxp3-) in Kras* On and Kras* off (5 days
and 4 weeks) PiKT mice (n=3-7 mice). Scale bars, 100μm. In (b-d), data are presented
as the mean ± SD. Significance was determined by Unpaired T-test (parametric or nonparametric). *P<0.05, **P<0.01, ***P<0.001, **** P<0.0001, ns: not significant. This work
was done with the help and collaboration of Dr. Elena Ramirez.
Chapter 4: CD4+T cells impede the therapeutic efficacy of Kras* targeting in PDAC
i)

CD4+ and CD8+ T cells do not alter primary tumor growth or survival,
but CD4+ T cells promote metastasis in PDAC

Next, we functionally probed the role of distinct T cell populations noted to increase
in the PDAC TME following Kras* suppression (R Fig. 3-4). We bred CD4-/(Cd4tm1Mak)(Rahemtulla et al., 1991) or CD8-/- (Cd8atm1Mak)(Fung-Leung et al., 1991) mice
with Pdx1-Cre; LSL-KrasG12D/+; P53R172H/+ (KPC) to generate CD4-/-; Pdx1-Cre; LSLKrasG12D/+; P53R172H/+ (KPC CD4-/-) and CD8-/-; Pdx1-Cre; LSL-KrasG12D/+; P53R172H/+
(KPC CD8-/-) mice. Depletion of CD4+ and CD8+ T cells in the thymus and spleen of KPC
CD4-/- and KPC CD8-/- mice was confirmed by immunofluorescence staining (R Fig. 5ab). The depletion of CD4+ and CD8+ T cells in the tumor and intra-tumoral lymphoid
follicle of the KPC CD4-/- and KPC CD8-/- mice were confirmed in the pancreatic TME (R
Fig. 5c-d).
The KPC CD4-/- and KPC CD8-/- mice developed PDAC tumors with a similar
latency and median survival as the control KPC strain (R Fig. 6a). All three mice cohorts
succumb to similar tumor burden (R Fig. 6b). Analysis of primary tumor grade and
proliferation in these mice showed no significant differences between the KPC, KPC
CD4-/- and KPC CD8-/- mice (R Fig. 6c-e). Analysis of metastasis in these PDAC mice
revealed decreased liver metastasis in the KPC CD4-/- mice compared to the KPC and
KPC CD8-/- mice (R Fig. 6f-g). However, there was no significant difference in lung
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metastasis between any of the groups (R Fig. 6h). Our results point to CD4+ T cells as
a potential target to restrict liver metastases in PDAC patients.
R Figure 5
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R Fig. 5: KPC CD4-/- and KPC CD8-/- mice lack respective T cell populations in the
tumor and lymphoid organs. (a-b) CD4 and CD8 immunostaining (a) and
corresponding quantification (b) of % of CD4+ or CD8+ area of thymus and spleen of
KPC, KPC CD4-/- and KPC CD8-/- mice. n=2-4 mice in each group. (c) CD4 and CD8
immunostaining and corresponding quantification (d) of KPC, KPC CD4-/- and KPC CD8/mice tumors (also note staining in intra-tumoral lymphoid follicle- ITLF). n=3-7 mice in
each group. Data are presented as the mean ± SD. Significance was determined by
Unpaired T-Test (parametric or non-parametric). *P<0.05, **** P<0.0001, ns: not
significant.
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R Fig. 6: CD4+ and CD8+ T cells do not alter primary tumor growth or survival, but
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CD4+ T cells promote metastasis in PDAC. (a) Kaplan-Meier survival curve of
baseline KPC (n = 19), KPC CD4-/- (n = 13) and KPC CD8-/- (n = 11) mice. P value by
log rank test. (b) End point tumor weights of KPC, KPC CD4-/- and KPC CD8-/- mice. (ce) Representative H&E images and Ki67 immunostaining of KPC, KPC CD4-/- and KPC
CD8-/- tumors at end point, with quantification of Ki67 proliferation index, and relative
percentage of histological phenotypes. (f) Representative H&E images and CK 19
immunostaining of liver metastasis of KPC and KPC CD8-/- mice. (g-h) Quantification of
liver metastasis g), and lung metastasis h), of KPC, KPC CD4-/- and KPC CD8-/- mice.
In (b), (c), (g), (e) and (h) data represents mean ± SD. Scale bars, 100um. In (b), (c),
significance was determined by Unpaired (parametric) T test. In (e), significance was
determined by two-way ANOVA. In (g) and (h), significance was determined by
Unpaired (non-parametric) T test. *P<0.05, ns - not significant.
ii)

iExosomes targeting Kras* increase T cell infiltration in PDAC.

Next, we examine if the immune changes observed in the PiKP and PiKT mice TME
following Kras* extinction can be replicated by a Kras* targeting agent. To suppress
Kras* in PDAC bearing mice, we employed a previously developed therapeutic strategy
using iExosomes to deliver KrasG12D siRNA to tumors(Kamerkar et al., 2017, Mendt et
al., 2018). We analyze T cell infiltration in KTC tumors (Ptf1acre/+; LSL-KrasG12D/+;
Tgfbr2lox/lox) at an age matched time point (day44) and mice bearing KPC689 orthotopic
tumors (end point) treated with iExosomes from our previous studies(Kamerkar et al.,
2017). The experimental scheme of start of iExosomes treatment and injection of
orthotopic KPC 689 tumors are described in the figure below (R. Fig. 7a-d). The PDAC
TME following iExo treatment showed increased infiltration of CD4+ and CD8+ T cells in
both the KTC and KPC 689 tumor models compared to respective controls (R. Fig. 7ad). These result support that the iExosomes therapy phenocopied the immune TME
changes observed in genetic Kras* suppression (R Fig. 3).
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R. Figure 7
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R Fig. 7: iExosomes targeting Kras* increase T cell infiltration in PDAC. a)
Timeline of the experiment for KTC mice treated with iExosomes every 48h starting at
33days of age and sacrificed on day 44 for age matched tumor comparisons. (b) CD4
and CD8 immunolabeling and quantification of end point KPC 689 – control (n=4), KPC
689 – iExo (n=4) treated tumors. (c) Timeline of the experiment for B6 mice injected
with KPC 689 cells into pancreas at 8 weeks of age. iExo treatment started at 10w,
every 48h till end point. (d) CD4 and CD8 immunolabelling and quantification on end
point KPC 689 – control (n = 4) and KPC 689 – iExo (n = 5) treated tumors. In (b), (d),
Data represent mean ± SD. Significance was determined by Unpaired (parametric) T
test *P<0.05, **P<0.01. This work was done on tissue sections from a previous study
(39).
iii)

CD4+ T cells impede the therapeutic efficacy of iExosomes in PDAC
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Age-matched (14 weeks old) KPC, KPC-CD4-/- and KPC-CD8-/- mice with
comparable tumor volumes (R Fig. 8a-b) were placed on iExosomes regimen (see
Methods) and tumor progression was monitored by serial MRI measurements (R Fig.
8c-d). The assessment of tumor volumes by MRI showed tumor stasis in KPC mice
treated with iExosomes, which was abolished by the depletion of CD8+ T cells (R Fig.
8d-e). However, in the KPC CD4-/- mice, the tumor volumes plateaued in the majority of
the mice following iExosomes therapy (R Fig. 8e). The KPC CD4-/- mice demonstrated
enhanced tumor growth inhibition compared to the KPC mice following iExosomes
therapy. As previously reported(Kamerkar et al., 2017), iExosomes significantly
improve the survival of KPC mice (R Fig. 9a-d). The survival of the control groups of
KPC, KPC CD4-/- and KPC CD8-/- mice show no difference in survival although the
KPC CD8-/- mice seem to have a marginally longer survival than the KPC mice cohort
(R Fig. 9e).
The depletion of CD4+ T cells in KPC CD4-/- mice exaggerated the effects of Kras*
blockade compared to the control KPC and KPC CD8-/- animals, supporting that CD4+
T cells restrained the impact of Kras* targeting (R Fig. 9a, f, g). However, depletion of
CD8+ T cells in KPC CD8-/- eliminated the survival benefits offered by Kras* targeting
with iExosomes, indicating CD8+ T cells play a role in tumor control by Kras* targeting
in this model (R Fig. 9a, d). Collectively, the data suggests that tumor growth inhibition
by Kras* targeting agent(s) is maximized in the absence of CD4+ T cells. These data
support the view that CD4+T cells in PDAC TME exert a pro-tumorigenic effect through
its inhibitory subsets in Kras* suppressed tumors, further supporting the idea that
Tregs, TH2 and TH17 cells are a critical mediator of PDAC progression.
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R Fig. 8: CD4+ T cells impede the therapeutic effects of iExosomes in PDAC. (a)
Timeline of the experiment for KPC, KPC CD4-/-, KPC CD8-/- mice treated with
iExosomes every 48h starting at 14 weeks of age. Baseline MRI measurements were
done prior to enrollment into iExosomes treatment groups. Mice were subsequently
imaged by MRI at indicated time points. Untreated mice were also analyzed as control
groups. (b) Baseline tumor volume at 14 weeks of age by MRI in KPC, KPC CD4-/-, and
KPC CD8-/- mice. Data are presented as the mean ± SD. n=7-14 mice in each group.
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following iExosomes treatment. (d) Change in tumor volumes (based on MRI
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R Fig. 9. Kaplan-Meier survival curves of KPC, KPC CD4-/- and KPC CD8-/- mice
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Chapter 5: The gut microbiome co-operates with CD4+ T cells to impede Kras*
targeting in PDAC.
Several clinical and pre-clinical studies that investigated the heterogeneity of
responses to checkpoint immunotherapy in melanoma and PDAC demonstrated that
host bacterial diversity play a critical role in modulating T cell response in
immunotherapy(Gopalakrishnan et al., 2018, Riquelme et al., 2019). We investigated
whether the gut microbiome modulates CD4+ T cells in Kras* targeting therapy. Eight to
sixteen weeks old C57Bl/6 wild type (B6) and CD4-/- (same genetic background)
cohorts of mice were co-housed to normalize the gut microbial flora. In addition, two
doses of fecal microbiota transfer (FMT) were performed one week apart to normalize
the gut microbiome across different study groups (R Fig.10a). Two weeks later, two
cohorts of B6 mice and one cohort of CD4-/- mice were administered broad spectrum
antibiotics (Abx) till end point (see methods). Both antibiotics treated and untreated
mice were orthotopically injected with 106 bioluminescent KPC689 cells (R Fig.10a).
16s rRNA quantitative PCR analysis of the bacterial DNA in the fecal pellets of Abx
treated and untreated group showed a significant decrease in bacterial DNA in the gut
of Abx treated mice (R Fig.10b). 16s rRNA sequencing revealed that Prevotellaceae,
Bacteroidales, Erysipelotrichaceae, Bacteroidaceae, and Helicobacteraceae were the
most abundant bacteria by family in the gut of untreated B6 and CD4-/- mice (R
Fig.10c). As previously reported(Kamerkar et al., 2017), iExosomes significantly
improve the survival of KPC689 tumor bearing (R Fig.10d). In contrast, the Abx
treated B6 mice compared to untreated B6 mice did not show any difference in survival,
and Abx treatment did not impact response to iExosomes therapy (R Fig.10d).
However, when the CD4+ T cells are depleted, microbiome ablation resulted in further
increase in survival with iExosomes therapy than when the microbiome is kept intact (R
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Fig.10e). Baseline IVIS imaging after two weeks following tumor injection did not show
any significant differences in tumor growth in Abx treated compared to untreated mice
(R Fig.11a-b). Following baseline IVIS imaging (R Fig.11a-b), iExosomes treatment
was initiated and continued until experimental endpoints (R Fig.10a). Further analysis
of bacterial populations at a species level resolution revealed that Muribaculum
intestinale, Parabacteroides distasonis, Bacteroides acidifaciens, Bacteroides sartorii,
and Bifidobacterium pseudolongum were among the most abundant bacteria
classifiable at the species level (R Fig.11c).
Collectively these findings support that the impact of Kras* targeting in the context of
impaired Tregs (CD4-/-) is aided by suppression of the microbiome.
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R Fig. 10: The gut microbiome co-operates with CD4+ T cells to impede Kras*
targeting in PDAC. (a) Timeline of the experiment for B6 and CD4-/- mice treated with
iExosomes and broad-spectrum antibiotics (Abx) (b) qPCR analysis for bacterial 16s
rRNA copy number per fecal pellet of mice treated with broad spectrum antibiotics (Abx)
vs. untreated control (d28). (c) Phylogenetic composition of fecal samples of untreated
(n = 6) and Abx treated (n = 8) mice at the bacterial family level (>0.1% abundance). (d)
Kaplan Meier survival curves of mice bearing orthotopic KPC 689 tumors with or without
microbiome ablation. B6-untreated (n=11), B6-iExo (n=5), B6-Abx (n=15), B6-iExo+Abx
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(n=11) mice. (e) Kaplan Meier survival curves of mice bearing orthotopic KPC 689
tumors, CD4-/- untreated (n=5), CD4-/- iExo (n=5), and CD4-/- iExo+Abx (n=5) mice. #
denotes low amounts of 16s rRNA. Data are presented as the mean ± SD. Significance
was determined by Unpaired T-test (parametric) (b), and log rank test (d, e). *P<0.05,
**P<0.01, ***P<0.001, ns: not significant. This work was done with the help and
collaboration of Dr. Hikaru Sugimoto, Dr. Robert Jenq and Dr. Chia-Chi Chang.
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iExo (n=4) and CD4-/- iExo+Abx (n=5) treated mice. (c) Detailed phylogenetic
composition of fecal samples at species level resolution, related to R Fig. 10c. # denotes
low amounts of 16s rRNA. (d) Kaplan Meier survival curves of mice bearing orthotopic
KPC 689 tumors, B6- Untreated (n=15) Vs. CD4-/- untreated (n=5) mice, related to R Fig.
10d-e. Data are presented as the mean ± SD. Significance was determined by Unpaired
T test (parametric or non- parametric) in (a) and (b), and log rank test in (d). **P<0.01,
**** P<0.0001, ns: not significant. This work was done with the help and collaboration of
Dr. Robert Jenq and Dr. Chia-Chi Chang
Chapter 6: CD4+ T cells promote tumorigenesis in KC mice with pancreatitis but
have no impact on spontaneously developing tumors.
i)

CD4+ T cells promote tumorigenesis in KC mice acute pancreatitis

To understand the distinct functions of T cells in spontaneously arising tumors
and tumors with underlying pancreatitis, we analyzed tumor initiation in spontaneously
developing PanIN lesions and pancreatitis induced mice. We crossed CD4-/- or CD8-/mice with Pdx1-Cre; LSL-KrasG12D/+ (KC) and generated CD4-/-; Pdx1-Cre; LSLKrasG12D/+(KC CD4-/-) and CD8-/-; Pdx1-Cre; LSL-KrasG12D/+ (KC CD8-/-) mice. To
assess spontaneous tumor initiation in KC, KC CD4-/- and KC CD8-/- mice, we
compared age matched mice sacrificed at a mean age of 200 days. Analysis of PanIN
lesions in these three cohort of mice showed no significant differences in tumor
initiation as seen by histological phenotypes (R Fig. 12a-b) or CK19 immunostaining (R
Fig. 12a, c). None of the KC mice had any evidence of invasive cancer in our cohort.
To understand the influence of underlying pancreatitis on PDAC initiation, we treat 6w
old KC, KC CD4-/- and KC CD8-/- mice with caerulein, an analogue of cholecystokinin
which has been implicated in the pathogenesis of human pancreatitis. These mice were
sacrificed 3 weeks later to assess tumor initiation (R Fig. 12d). We chose this time
point for sacrifice as 3 weeks as it was optimal to assess adaptive immune response at
this time point. Pancreatitis accelerated tumor initiation in KC mice (Compare PanINs in
KC mice w/o caerulein Vs. KC acute pancreatitis (R Fig. 12e-f) as seen by histological
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phenotypes and CK 19 immunostaining (R Fig. 12e-g). However, we observed that KC
CD4-/- mice had relatively fewer PanIN lesions compared to KC and KC CD8-/- mice (R
Fig. 12e-g). Thus, our results suggest that CD4+ T cells promote tumor initiation in
mice with underlying pancreatitis, whereas have no impact on tumor initiation in
spontaneously developing PanINs.
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spontaneously progressing KC mice (age matched sacrifice at ~ 200 d from birth). (b)
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Relative percentages of histological phenotypes. (c) Quantification of CK19 positive
area in the pancreas. In (a-c), KC (n= 5), KC CD4-/- (n=6) and KC CD8-/- (n=6). (d)
Schematic representation of acute pancreatitis induction with experimental treatment
time points. Caerulein administration induces pancreatitis in KC mice in contrast to
spontaneously progressing PanINs. (e) Representative H&E and CK19 immunostaining
of PanIN lesions of mice with and without caerulein treatment. (f) Quantification of
CK19 positive area in the pancreas from (f). (g) Relative percentages of histological
phenotypes. In (e-g), KC w/o caerulein (n=4), Acute pancreatitis- KC (n= 5), KC CD8-/(n=6) and KC CD4-/- (n=3). In (b), (c), (f) and (g), data represents mean ± SD. In (b, g),
significance was determined by two-way ANOVA and in (c, f) significance was
determined by Unpaired (parametric) T test, * P < 0.05, ** P < 0.01, *** P < 0.001, ****
P < 0.0001, ns- not significant.
ii)

CD4+ T cells promote tumorigenesis in KC mice with chronic
pancreatitis

Next, we probe the role of CD4+ T cells in tumor initiation in a setting of
underlying chronic pancreatitis. Chronic pancreatitis is observed in 10% of patients with
PDAC (R Fig. 13a). Frequently, patients with pancreatic cancer develop bile duct
obstruction due to tumors impinging on the bile duct leading to chronic pancreatitis. In
the clinical setting, chronic pancreatitis is usually a result of multiple acute insults to the
pancreas commonly due to repeated alcohol use and intermittent gallbladder
obstruction due to tumor invading the bile duct. We probe whether depletion of CD4+ T
cells restrict tumor initiation in a chronic pancreatitis setting. To mimic the development
of chronic pancreatitis in humans, we inject KC, KC CD4-/- and KC CD8-/- mice with
caerulein 4 times a day, three times a week for 3 weeks (R Fig. 13b). These mice were
sacrificed 8 weeks later to assess tumor histology. Consistent with our findings in KC
mice with acute pancreatitis, CD4+ T cells promote tumorigenesis in KC mice with
chronic pancreatitis. KC CD4-/- mice had fewer PanIN lesions compared to KC and KC
CD8-/- mice as seen by tumor histology and CK 19 immunostaining (R Fig. 13c-e).
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In of(e),
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5, KC CD8-/- : n=4 and KC CD4-/- n=4). (E) Two-way ANOVA table comparing histological phenotypes in (D). (F) Quantification of CK19 positive area in the
(d) significance
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(parametric)
T
tests,
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representnsSEM, Significance
was determined by T tests (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, NS- not significant). See also supplementary
figure 4.

iii)

Kras* protects the pancreas against acute pancreatic injury:
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Metaplasia is frequently a response associated with infections and inflammation where
one form of differentiated epithelium transforms into another. It is essentially a
protective response which reverses once the inciting stimulus or inflammation
subsides. When the injury to the tissue continues, the epithelium undergoes
transformation resulting in intra-epithelial neoplasia (pre-malignant lesions). This is
commonly observed in the gastro-esophageal (GE) junction where acid reflux
commonly results in intestinal metaplasia and GE junction tumors. However,
metaplasia and intra-epithelial neoplasia are replaced by the native functional
epithelium once the injury to the tissue subsides. Here, we observe that Kras*
accelerates ADM and PanIN formation (R Fig. 12e-g) and hypothesize that Kras*
protects the pancreatic epithelium against pancreatitis by accelerating ADM/ PanIN
formation. We induce pancreatitis in mice with and without Kras* expression in the
pancreas and subsequently compare the levels of enzymes associated with pancreatic
injury (R Fig. 14a-d). Increase in pancreatic amylase and lipase levels in the blood
combined with a decrease in fecal elastase levels are hallmarks of clinical
pancreatitis(Engle et al., 2019). We observed that both pancreatic amylase and lipase
levels are elevated in both KC and Cre negative mice quickly after caerulein
administration, continue to rise after day 3, and eventually fall by day18 and further
lower on day 22 (4 days after last dose of caerulein – post caerulein D4) (R Fig. 14ab). However, we observed that KC mice had 3 times lower amylase and 19 times lower
lipase levels at the peak compared to their Cre negative counterparts (R Fig. 14d). We
observed that KC mice and Cre negative mice show similar baseline levels of
pancreatic amylase and lipase (R Fig. 14d). Fecal elastase levels in KC mice with
pancreatitis is significantly reduced compared to age matched KC mice without
pancreatitis (R Fig. 14c). These results suggest that Kras* protects the pancreas
62

against acute pancreatic injury, whereas the protective effect on the epithelium is lost in
a setting of chronic pancreatitis. Our results suggest that the pancreatic acini eventually
develop tolerance to repeated pancreatic injury and becomes unresponsive to
cholecystokinin stimuli. Therefore, Kras* accelerates tumorigenesis, whereas offers
little protection against chronic pancreatitis in our mouse model.
R Figure 14
a

c

b

d

R Fig. 14: Kras* protects the pancreas against acute pancreatic injury. (a-b)
Plasma amylase levels and lipase levels in KC mice (a), and cre negative mice (b),
without caerulein Vs. caerulein treated mice at indicated experimental time points. (c)
Fecal elastase levels in KC mice without caerulein Vs. caerulein treated mice. (d)
Comparison of mean plasma amylase and lipase levels in Cre- Vs. KC mice with
chronic pancreatitis. In (a-c), data represents mean ± SD. n = 2-9 mice in all cohorts. In
(a), (b), (c) and (d), significance between groups was determined by Unpaired
(parametric and non-parametric) T test. * P < 0.05, ** P < 0.01, *** P < 0.001, **** P <
0.0001, ns- not significant.

Supplementary figure4: Mutant Kras protects the pancreas against acute pancreatic injury. Plasma
amylase(a) and lipase (b) levels in spontaneous Vs. caerulein treated KC mice at indicated
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Chapter 7: CD4+ T cells regulate dendritic cells to facilitate pancreatic
tumorigenesis in mice with underlying pancreatitis.
i)

Pancreatitis recruits CD11c+ dendritic cells to the PDAC TME
Now that we established that T cells play distinct roles in spontaneously arising

PDAC and PDAC arising in the setting of pancreatitis, we further probe the
differences in the tumor microenvironment of the spontaneous and pancreatitis
associated PDAC. Spontaneous KC mice and KC mice with acute pancreatitis had
similar tumor stage as seen by tumor histology and CK19 immunostaining (R Fig.
15a-b). Analysis of different immune sub-populations from the TCGA datasets in
PDAC patients with and without a history of chronic pancreatitis revealed a higher
number of dendritic cells in patients with a history of chronic pancreatitis (R Fig.
15c). We used an online platform CIBERSORT to analyze relative abundances of a
member cell type in a mixed population of bulk expression (RNA sequencing) data.
Next, we analyzed if there were any differences in myeloid, macrophage and
dendritic cell populations between spontaneous and pancreatitis associated PDAC
in KC mice. There were no significant differences in CD11b+ myeloid populations by
CD11b by immunostaining between the two groups (R Fig. 15d, e), whereas there
was a significantly higher infiltration of dendritic cells in pancreatitis associated
PanINs (CD11c immunostaining, R Fig. 15d, e). Further, we compare the T cell
infiltration in these stage-matched tumors. Among the CD4+ T cells, there was no
significant difference in the way the CD4+ T cells polarized [Spontaneous Vs.
Pancreatitis associated PDAC: Tregs (44% Vs. 48%), TH1(0.32% Vs. 0.4%), TH2
(30% Vs. 23%), TH17(21% Vs. 17%) (R Fig.15f).
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R Figure 15
a

c

b

P = 0.009
130

Chronic Pancreatitis Personal Medical History Indicator
NO: 130 (70.3%)
YES: 13 (7.0%)
NA: 42 (22.7%)

d

KC - AP

e

Cd11b

CD11c

KC - S

f

KC - AP

DAPI/ CD4/ GATA3

DAPI/ CD4/ RORγt

DAPI/ CD4/ FoxP3

KC - S

R Fig. 15: Pancreatitis recruits activated dendritic cells to the tumor
microenvironment. (a) Relative percentages in histological phenotypes in
spontaneous (KC-S) and acute pancreatitis (KC-AP) mice. (b) Quantification of CK19
positive area in the pancreas of KC-S and KC-AP mice. (c) Analyses of patients with
known history of chronic pancreatitis from TCGA datasets. Dendritic cells as a fraction
of tumor infiltrating cells from TCGA dataset (analyzed by CIBERSORT, P represents
adjusted P value, FDR < 0.01). (d-e) Representative images of CD11c and CD11b
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immunostaining in KC-S and KC-AP mice and quantification. (f) Representative images
and quantification of CD4/FoxP3 (Treg), CD4/RoRgt (TH17) and CD4/GATA3 (TH2)
immunolabelling in KC-S and KC-AP mice. In (a), (b), (e) and (f), data represents mean
± SD. In (a), significance was determined by two-way ANOVA and
in (b), (e) and (f) significance was determined by Unpaired (parametric) T-test, *** P <
0.001, ns- not significant.
ii)

CD4+ T cells regulate dendritic cells to drive tumor initiation in mice
with acute pancreatitis

Studies have shown that regulatory T cells inhibit tumor associated dendritic cells
and restrain expression of co-stimulatory ligands necessary of activation of cytotoxic
lymphocytes in PDAC(Jang et al., 2017). Therefore, we hypothesize that depletion of
CD4+ T lymphocytes removes the brakes on tumor associated dendritic cells in
caerulein treated KC CD4-/- mice. In our spontaneous KC model of PDAC, the depletion
of CD4+ T cells did not result in restriction of tumor initiation due to lack of dendritic
cells and antigen presentation in these tumors (R Fig. 12a-c). However, induction of
pancreatitis resulting in accumulation of dendritic cells facilitate immune-modulation of
these tumors. The depletion of the inhibitory CD4+ cells in these KC mice with
pancreatitis removes its inhibitory infiluence on the dendritic cells, enabling tumor
growth inhibition in these mice. To establish that the activated dendritic cells restrict
tumor initiation in the KC CD4-/- mice with pancreatitis, we deplete the dendritic cells in
these mice with an inhibitory aCD11c antibody (R Fig. 16a). Depletion of CD11c+
dendritic cells resulted in rescue of tumor initiation in the KC CD4-/- mice as seen by
tumor histology and CK19 immunostaining (R Fig. 16b-d). In conclusion, CD4+ T cells
render dendritic cells tolerogenic in pancreatitis associated PDAC mice.
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R Figure 16
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R Fig. 16: CD4+ T cells regulate dendritic cells to drive tumor initiation in mice
with pancreatitis. (a) Schematic representation of acute pancreatitis induction with
⍺CD11c or isotype treatment time points in KC CD4-/- mice. (b) Representative H&E
and CK19 images of PanIN lesions of with ⍺CD11c or isotype treated KC CD4-/- mice.
(c)Figure4:
Quantification
of CK19 positive area in the pancreas. (d) Relative percentages of
CD4+ T cells promote tumorigenesis in KC mice with pancreatitis by restraining dendritic cells. (a) Schematic representation of acute
pancreatitis
induction
with
⍺CD11c
or isotype
treatment
time way
points inANOVA
KC CD4-/- mice.table
(b) Representative
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twofrom (b).
(KC
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5), lesions
KC of
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(e) Two-way
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= 4) mice.
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In (c) significance was determined by Unpaired (parametric) T-test, * P < 0.05, **** P <
0.0001, ns- not significant.
Error bars represent SEM, Significance was determined by T tests (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, NS- not significant).

iii)

Pancreatitis renders the pancreatic TME sensitive to checkpoint
blockade
Next, we question whether presence of underlying pancreatitis would render the

pancreatic cancers sensitive to checkpoint blockade. Multiple studies in patients
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and in pre-clinical models have established that checkpoint immunotherapy has
failed to produce durable survival responses in PDAC. We investigate whether
combination of aCTLA4/PD1 or aPD1 monotherapy would produce a tumor growth
inhibitory response in KC mice in the presence of antigen presenting dendritic cells
recruited during acute pancreatitis (R Fig. 17a). When the KC mice were sacrificed
3 weeks later for analysis of immunotherapy response, we observed that there was
a decrease in PanINs in the aCTLA4/PD1 and aPD1 treated KC mice with
pancreatitis compared to the Isotype and untreated KC mice with acute pancreatitis
(R Fig. 17b-c). Therefore, we establish that presence of underlying pancreatitis
sensitizes the tumor-microenvironment for checkpoint blockade in KC mice.
a
⍺CTLA4/PD1

⍺CTLA4/PD1

Mouse age ~ 6w
Caerulein - Day 0

R Figure 17
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b
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Histology
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⍺CTLA4/PD1
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KC ⍺PD1
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P ***
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R Fig. 17: Pancreatitis renders the pancreatic TME sensitive to checkpoint
blockade. (a) Schematic representation of acute pancreatitis induction with
⍺CTLA4/PD1 or isotype treatment time points in KC mice. (b) Representative H&E
images of PanIN lesions of with ⍺CTLA4/PD1, ⍺PD1 or isotype treated KC mice. c)
Relative percentages in histological phenotypes and two-way ANOVA table from (b),
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KC (n= 5), KC Isotype (n = 2), KC ⍺PD1 (n = 2) and KC ⍺CTLA4/PD1 (n=4). In (c), data
represents mean + SD. * P < 0.05, ** P < 0.01, *** P < 0.001.
Summary of results:
In this study, we first analyze how Kras* modulates the immune microenvironment in
PDAC. We utilize an inducible and pancreas specific Kras* expressing murine model
that can be manipulated by addition or withdrawal of doxycycline to control Kras
expression. Extinction of Kras* led to global increases in T cell populations and
reduction in the myeloid infiltrate in the TME. Although there was a reversal of
immunosuppressive TME, we also found an increase in suppressor CD4+ T lymphocyte
population following Kras* extinction. Extinction of Kras* also resulted in improved
survival of the PDAC mice, regression of established PDAC tumors, desmoplasia and
chronic fibrosis. Next, we examine if the immune phenotype observed with the
inducible murine model can be realized with a therapeutic agent targeting Kras*.
Towards this end, we examine the impact of iExosomes targeting Kras* on the TME.
We observed that following Kras* targeting therapy, multiple PDAC models
demonstrate an increase in T cell population in the TME, mimicking the phenotype
observed in the PiKP and PiKT mice. Next, we probe the functional contribution of
distinct T cell populations that increase following iExosomes therapy in the TME. We
crossed KPC with CD4-/- and CD8-/- mice to generate KPC, KPC CD4-/- and KPC CD8-/mice cohorts.
Depletion of CD4+ T lymphocytes enhanced the therapeutic efficacy of Kras* targeting
compared to controls and CD8 knockout mice, whereas depletion of CD8+ T
lymphocytes diminished its therapeutic efficacy. Analysis of the role of CD4+ and CD8+
T cells in primary PDAC progression revealed similar tumor latency, median survival
and proliferation in the KPC, KPC CD4-/- and KPC CD8-/- mice. However, the depletion
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of CD4+ T cells in a KPC model showed decreased liver metastasis compared to
controls and CD8 knockout mice.
Next, we explore the differences between spontaneously arising PanINs and
PanINs arising in a TME with underlying pancreatitis. We assess tumor initiation at an
age matched time point (~200 days in all groups) between the KC, KC CD4-/- and KC
CD8-/- mice. No differences in tumor initiation were observed between these groups in
mice spontaneously developing tumors. However, in the setting of acute pancreatitis in
these mice, KC CD4-/- mice did not develop PanIN lesions, suggesting that CD4+ T
cells promote tumorigenesis in mice with pancreatitis. Next, we confirmed our findings
in KC CD4-/- mice with a chronic pancreatitis model. A phenotype similar to that
observed in acute pancreatitis was observed in the chronic model. Further, we probe
the differences in immune infiltrate between the spontaneous and pancreatitis driven
KC mice cohorts. We observed an upregulation of CD11c+ dendritic cells in the TME of
KC mice with acute pancreatitis. In addition, a similar increase in dendritic cell
population was also observed in the human PDAC patients with a known history of
chronic pancreatitis. We probe the interactions between dendritic cells and CD4+ T
cells by depletion of CD11c+ dendritic cells in the KC CD4-/- mice. Depletion of dendritic
cells in KC CD4-/- mice rescued tumor initiation in the KC CD4-/- mice indicating that
CD4+ T cells inhibit dendritic cell populations, promoting tumorigenesis in KC mice with
pancreatitis. Next, we assess if increased antigen presentation in KC mice with
underlying pancreatitis render them sensitive to checkpoint blockade. Treatment of KC
mice in a setting of acute pancreatitis with aCTLA4 and aPD1 antibody resulted in
inhibition of tumorigenesis compared to the control and isotype treated KC mice.
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However, treatment with aPD1 antibody alone resulted in a sub-optimal inhibition of
tumorigenesis.

Chapter 8: Discussion
Role of Kras* in shaping the PDAC TME
Although mortality and disease outcomes of several cancers have improved
substantially over the last decade, pancreatic cancer outcomes have only improved
marginally (Fig. 1). One recent breakthrough that has improved disease outcomes in
melanoma, non-small cell lung cancer and lymphomas is cancer immunotherapy.
However, PDAC is among the cancers that is resistant to checkpoint immunotherapy
(2, 3). The mechanisms behind a lack of response to immunotherapy remains poorly
understood due to fundamental gaps in knowledge of understanding the
immunobiology of PDAC.
One study that analyzed the fundamental differences in the tumor
microenvironment of PDAC and melanoma attributed the lack of response to
immunotherapy to a T cell deficient milieu and lack of TH1 cells in PDAC (Blando et al.,
2019). T cells function by cell-cell contact and hence proximity of the T cells to the
tumor cells is an important predictor of T cell response in cancer(Carstens et al., 2017).
Studies in murine colonic adenocarcinoma model with Kras* expression demonstrated
that Kras* suppressed T cell infiltration, promotes MDSCs and rendered the Kras*
mutant colonic adenocarcinomas resistant to checkpoint immunotherapy(Liao et al.,
2019). However, clinical data in NSCLCs suggests that presence of mutant Kras
rendered the lung cancers susceptible to checkpoint immunotherapy. The differences
in disease phenotypes in these models most likely stem from the disparate roles of
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Kras* in different tumor settings. While Kras* has been established to be a principle
driver mutation in PDAC, Kras* mutation is not as ubiquitous in colonic
adenocarcinoma or NSCLCs(Liu et al., 2020). A majority of NSCLCs do not have
known driver mutations and mutations in Kras* might have varied roles in different
tumor contexts in the presence of other passenger or co-existing driver mutations.
In our study, we use inducible iKras* GEMMs, with either P53 or Tgfbr2
conditional null alleles. Upon induction of Kras*, both the tumors exhibited similar
dependency on Kras* for survival and growth, and enabled a comprehensive analysis
of the role of Kras* on PDAC immune microenvironment. We probe the functional
contribution of Kras* in shaping the TME by extinction of Kras* in mice with established
PDAC. Our results suggest that Kras* plays an important role in creating a T cell
deficient and myleoproliferative TME in PDAC that renders it resistant to T-cell
targeting therapies. Genetic extinction of this oncogenic signal led to the recruitment of
T cells, depletion of myeloid cells and transforms the immunologically ‘cold’ TME into a
‘hot’ one. Interestingly, Kras* extinction also increased the infiltration of
immunosuppressive T regs in the TME in addition to reversing the T cell deficient and
myeloproliferative TME. Further, consistency of the phenotype observed in two models
with different co-existing mutations establishes that Kras* represents the principle
driver in shaping the immune microenvironment in PDAC, and presence of other
mutations did not affect the nature of the immune infiltrate. In addition to shaping the
immune microenvironment, our results suggest that Kras* promotes desmoplasia and
chronic fibrosis, two of which pose major challenges to delivery of drugs and T cell
infiltration in PDAC(Provenzano et al., 2012).

Role of CD4+ and CD8+ T cells in PDAC progression
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Next, we probe the role of CD4+ and CD8+ T cells in a spontaneously model of
PDAC by depleting different T cell populations in KPC mice. Studies analyzing T cell
infiltration in PDAC suggest that proximity of CD8+ T cells to pancreatic cancer cells
correlate with better survival outcomes(Carstens et al., 2017). T cells in PDAC can be
classified as either pro-tumorigenic or anti-tumorigenic based on their specific roles in
PDAC progression. Studies using murine PDAC models demonstrate that ab T
cells(Daley et al., 2016), CD4+ T cells(Zhang et al., 2014), TH17 cells(McAllister et al.,
2014), TH2 cells(Dey et al., 2020) and CD11b+(Zhang et al., 2017) myeloid cells
promote tumorigenesis, whereas dendritic cells and CD8+ T lymphocytes restrict PDAC
progression(Jang et al., 2017, Pushalkar et al., 2018).
We utilize a murine PDAC (KPC model) that closely mimics the development of
human pancreatic cancer to understand the effects of depletion of specific T cell
populations. The KPC model represents a penetrant model for metastasis as more than
half the mice develop liver metastasis and a small portion of the mice develop lung
metastasis. However, unlike in humans, most mice in the KPC model die due to
primary tumor burden rather than metastasis. In our KPC model, we found that
depletion of CD4+ T cells in PDAC, attenuated liver metastasis. Despite a trend towards
decrease in lung metastasis, no significant differences were observed in lung
metastasis with depletion of CD4+ T cells as lung metastases were less frequent and
not as robust as liver metastasis in the KPC model. However, depletion of CD4+ or
CD8+ T cells did not alter primary tumor growth or survival. A similar murine breast
cancer model that crossed the MMTV-PyMT model with the CD4 and CD8 knockout
mice demonstrated decreased lung metastasis in the mice with depletion of CD4+ T
cells(DeNardo et al., 2009). The authors further demonstrate that CD4+ T cells impact
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metastasis by regulating Gr1- macrophages, which in turn promote metastasis in these
murine breast cancer mice(DeNardo et al., 2009).

Adaptive immune response and gut microbiome in Kras* targeting therapy:
Next, we probe the specific roles of CD4+ and CD8+ T cells in the therapeutic
targeting of KrasG12D mutation. We employed iExosomes to target Kras* in the context
of CD4+ and CD8+ T cell depletion in the KPC model. We observed in our PiKP and
PiKT models that Kras* extinction promotes T cell infiltration in the PDAC TME.
Further, we question if such a dominant role of Kras* can be translated clinically using
a therapeutic agent to target Kras*. iExosomes targeting Kras* demonstrated an
increase in CD4+ and CD8+ T cell populations in the TME following Kras* targeting.
Thus, the proof of concept studies firmly establish our hypothesis that Kras*
predominantly drives T cell suppression, and that therapeutic Kras* targeting could
potentially render the PDAC TME amenable to T cell targeting strategies. Depletion of
CD4+ T cells in the KPC model enhanced tumor growth inhibitory response following
Kras targeting while depletion of CD8+ T cells counteracted its benefits. Our results
suggest that CD4+ T cells are suppressive in nature (predominantly T regs, TH2, TH17
with minimal TH1 infiltration) and constitute the majority of the T cell infiltrate in PDAC.
Depletion of these immunosuppressive CD4+ T cells facilitate the anti-tumor response
of CD8+ T cells in PDAC.
The gut microbiome has been demonstrated to exert a critical influence as an
extrinsic modulator of T cell response in multiple studies of melanoma and
NSCLCs(Gopalakrishnan et al., 2018, Sivan et al., 2015). Analysis of the intra-tumoral
microbiome in human PDAC revealed that presence of Gammaproteobacteria in PDAC
contributed to resistance to gemcitabine therapy(Geller et al., 2017).
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Gammaproteobacteria degrades gemcitabine to its inactive form, 2′,2′difluorodeoxyuridine. A murine study analyzing the impact of gut microbiome in PDAC
demonstrated that the gut microbiome promotes tumorigenesis and tumor progression
by restricting the CD8+ T cell response(Pushalkar et al., 2018). Further, the authors
demonstrate that the depletion of the gut microbiome renders PDAC tumors sensitive
to checkpoint immunotherapy(Pushalkar et al., 2018). In contrast to the previously
published data, our data suggests that depletion of the gut microbiome did not alter
tumorigenesis or Kras* targeting response. However, the gut microbiome facilitates
CD4+ T cells and depletion of the gut microbiome together with CD4+ T cells
significantly improved the survival of pancreatic cancer mice following Kras* targeting
therapy. The presence of CD4+ T cells over-ride the effects of depletion of gut
microbiome in our PDAC model.

Impact of pancreatitis on adaptive immune response in PDAC:
In the next part of our study, we question how underlying pancreatitis alters the
tumor microenvironment and disease progression in PDAC. Analysis of TCGA datasets
revealed that ~10% of PDAC patients have had a known history of chronic pancreatitis.
Further analysis revealed that these patients had a higher proportion of dendritic cells
in their TME, suggesting enhanced antigen presentation in the tumor microenvironment
of these mice. In addition to patients with a known history of chronic pancreatitis,
obstruction or invasion of the hepato-pancreatic duct during the course of pancreatic
cancer can evoke pancreatitis in a substantial portion of patients. We hypothesize that
presence of pancreatitis in PDAC functionally alters the nature of the TME and opens
new opportunities for targeting the adoptive immune response in PDAC.
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We observed no difference in tumorigenesis in our KC mice with depletion of
CD4+ and CD8+ T cells. However, other studies that used murine models of PDAC to
analyze the role of CD4+ and CD8+ T cells in PDAC demonstrated that CD4+ T cells
promotes tumorigenesis(McAllister et al., 2014, Zhang et al., 2014). When we probed
the reasons for difference in phenotype between our model and that of others, we
found that the other studies utilize a caerulein induced pancreatitis model, whereas our
study analyzed the impact of T cells in a spontaneously progressing model of PDAC.
Chronic pancreatitis poses a significant risk factor for the development of PDAC.
Multiple murine models of PDAC have shown chronic pancreatitis to accelerate the
progression of PDAC. Next, we see if we could replicate the findings from other studies
in our murine models. Induction of pancreatitis altered the functional outcome of the
CD4+ T cells in our model. We observed that in the setting of both acute and chronic
pancreatitis, CD4+ T cells promote tumorigenesis. These findings led us to analyze the
functional differences in the pancreatic immune microenvironment induced by the
presence of underlying pancreatitis. We found no differences in myeloid, TH1, TH2,
TH17 and regulatory T cells between the spontaneous and the pancreatitis induced
models of tumorigenesis. The pancreatitis induced KC mice, however demonstrated
higher number of CD11c+ dendritic cells compared to the spontaneously progressing
PDAC mice. The similarities in the dendritic cell phenotypes induced by pancreatitis
between the human datasets and our murine models prompted us to further explore the
cross talk between dendritic cells and CD4+ T cells in the KC models with pancreatitis.
We hypothesize that the CD4+ T cells exert inhibitory influence of dendritic cells thereby
prevent the development of an anti-tumor response. Therefore, depletion of CD4+ T
cells in a pancreatitis setting that recruit dendritic cells to the TME prevent
tumorigenesis. Further, depletion of dendritic cells in the CD4+ T cell depleted mice
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rescued tumor development in these mice highlighting the importance of dendritic cellCD4+ T cell axis in the TME.

Role of dendritic cells in sensitizing the PDAC TME to immunotherapy
Next, we examine if the dendritic cells recruited in the process of pancreatitis
render the KC mice susceptible to checkpoint blockade. Several lines of studies
demonstrate that checkpoint immunotherapies failed to produce tumor growth inhibition
in clinical trial and preclinical models of PDAC (2,3). However, in the setting of acute
pancreatitis, combination checkpoint blockade with aCTLA4 and aPD1 antibodies
inhibit tumorigenesis, whereas monotherapy with aPD1 produced a partial tumor
inhibitory response. Collectively, our findings suggest that presence of activated
dendritic cells in the TME renders the KC mice sensitive to checkpoint blockade.
Collectively, our results offer rationale for stratification of patients with underlying
pancreatitis specifically for immunotherapy approaches in clinical trials.
Conclusion:
Our results offer mechanistic insights into the role of Kras* in shaping the
immune microenvironment in PDAC. The study demonstrates the potential for
combining Kras* and CD4+ T cell targeting therapies in PDAC. Further, our study offers
novel and systematic insights into how pancreatitis fundamentally alters the nature of
the TME. This novel finding opened a whole new range of therapeutic opportunities
from utilization of dendritic cell vaccines to stratifying patients for checkpoint
immunotherapy in clinical trials.
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